| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | BLA | — | Subscribe to access the data. | Biologics | Oncology | ||
PDUFA Date example | BLA | — | Subscribe to access the data. | Biologics | Oncology | ||
PDUFA Date example | BLA | — | Subscribe to access the data. | Biologics | Oncology |
Recent Updates
Recently added Catalysts
Summit Therapeutics Inc.$12.31
-0.79 (-5.99%)
B 63Pipeline Score Overvalued Biotech · Clinical
Market Cap
12.90 B
EPS
-1.60
P/E Ratio
-
Value Trade
65.15 M
SEC Financials
Q2 2026Dilution Risk
40%R&D Expenses
157.73 M
Total Assets
752.18 M
Total Liabilities
122.20 M
Equity
629.98 M
D/E Ratio
12,345
-6.52 %
Week
-37.61 %
1 Month
5.99 %
3 Month
1.34 %
6 Month
117.25 %
5 Year
65.87 %
All Time
Cash Data
Cash Position
690.68 M
Monthly Burn
71.90 M
Runway
9.4 mo
Burn Trend
SEC Filing
Jul 23, 2026
Overview
Volume
2.26 M
52 Week Range
13.83 - 30.98
% held by Insiders
83.15 %
% held by Institutions
15.52 %
Enterprise Value
12.32 B
Total Shares
777.87 M
Short %
28.55 %
Float Shares
134.57 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Summit Therapeutics Inc.
742Total events
5Upcoming
147Tier-1 (high impact)
2011 – 2026Coverage
Upcoming catalysts 2
TBD
T1PDUFA Date
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
◆Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
▲Full ResultsivonescimabApprovedClinical Data
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-09-08 | Ivonescimab | Phase 3 data readout | Phase 3 | — | – | – | – |
2024-09-08 | Ivonescimab | Phase 3 data readout | Phase 3 | — | – | – | – |
2024-09-08 | Ivonescimab | Phase 3 data readout | Phase 3 | — | – | – | – |
Drug Pipeline Intelligence
B63
Pipeline Score $5.8B
Pipeline ValueOvervalued
Valuation Signal8
Drugs Scored0.5x
rNPV / MCap Top 92%
Mid Cap (rank 74 of 913)
Percentile RankSummit Therapeutics Inc. holds a solid B-grade pipeline (63/100), with $6.9B risk-adjusted pipeline value, led by Ivonescimab in Non-Small Cell Lung Cancer (Phase 3), across $124B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ivonescimab Monoclonal antibody | Non-Small Cell Lung Cancer | Phase 3 | NCT05899608 | 48% | $3.3B | RECRUITING | 2,380 | VERY_FAST | B (65) | Dec 31, 2029 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Ivonescimab | squamous non-small cell lung cancer (NSCLC) | Phase 3 | 2026-05-31 | hazard ratio: 0.66; os rate ivonescimab: 64.7%; os rate tislelizumab: 48.6%; median follow up: 21.4 months Read More | Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China Read More | |
Ivonescimab | squamous non-small cell lung cancer (NSCLC) | Phase 3 | 2026-05-31 | hazard ratio: 0.66; os rate ivonescimab: 64.7%; os rate tislelizumab: 48.6%; median follow up: 21.4 months Read More | Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China Read More | |
Ivonescimab | squamous non-small cell lung cancer (NSCLC) | Phase 3 | 2026-05-31 | hazard ratio: 0.66; os rate ivonescimab: 64.7%; os rate tislelizumab: 48.6%; median follow up: 21.4 months Read More | Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SMMT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SMMT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SMMT▼ -8.8%on this news
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
Summit Therapeutics Inc. reported its financial results for Q2 and the first half of 2026, highlighting significant operational advancements. The company emphasized the clinical progress of ivonescimab, particularly following promising results from the HARMONi-6 Phase III study. These developments are expected to strengthen their position in the market.
Read more →SMMTIvonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
Summit Therapeutics Inc. has reported updated overall survival results from the Phase III HARMONi trial, demonstrating that ivonescimab combined with platinum-doublet chemotherapy continues to show a favorable trend. The results indicate consistent efficacy and safety across both Asian and western patient populations compared to chemotherapy alone.
Read more →SMMT▼ -8.7%on this news
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
Summit Therapeutics Inc. will host a conference call on July 23, 2026, to discuss its second quarter financial results and operational updates. The call is set for 4:30 p.m. EDT and will be accessible via the company's website. This event highlights the company's commitment to investor relations and transparency.
Read more →SMMTSummit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
Summit Therapeutics has entered into an agreement to sell its Phase III asset, ridinilazole, to Biossil, Inc. This precision antibiotic was previously evaluated in the Phase III Ri-CoDIFy study. The transaction allows Summit to concentrate on other initiatives while Biossil aims to advance the drug for life-threatening conditions.
Read more →SMMTSummit Therapeutics Announces Proposed Public Offering of Common Stock
Summit Therapeutics has announced a proposed public offering of common stock. However, the article does not provide specific details about the offering, including the number of shares or pricing. The lack of information raises concerns about transparency and investor interest.
Read more →SMMT▼ -10.4%on this news
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
The article discusses the HARMONi-6 study conducted by Akeso in China, which compares Ivonescimab with chemotherapy against Tislelizumab plus chemotherapy for first-line treatment of patients with squamous non-small cell lung cancer (NSCLC). However, the article lacks specific details regarding the study's findings or implications.
Read more →SMMT▼ -10.4%on this newsshared move
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
The article discusses the presentation of Phase II data for Ivonescimab in first-line metastatic colorectal cancer at ASCO 2026. However, specific details about the data or outcomes are not provided in the text. The overall sentiment appears neutral due to the lack of detailed information.
Read more →SMMT▲ +5.4%on this news
Summit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims for investors of Summit Therapeutics Inc. following a significant stock decline after the company's first quarter 2026 financial report. The report revealed challenges related to the HARMONi-3 Phase III clinical trial, particularly concerning the interim progression-free survival analysis. Investors who suffered losses may have options for recovery under federal securities laws. The investigation centers on whether Summit complied with these laws amid the declining share price.
Read more →SMMTSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026
Summit Therapeutics reported its financial results and operational updates for Q1 2026, highlighting progress in clinical trials for ivonescimab, a bispecific antibody. The FDA has accepted the Biologics License Application for ivonescimab, with a PDUFA goal date set for November 14, 2026. Despite a significant increase in operating expenses and net loss, the company maintains a strong cash position.
Read more →SMMTMultiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
Summit Therapeutics announced that updated data on ivonescimab will be showcased at the ELCC 2026. The presentations will include findings from the global HARMONi Phase III study, demonstrating improved intracranial progression-free survival in patients with EGFR-mutated NSCLC. The data indicates potential benefits of ivonescimab when combined with chemotherapy, with no new safety concerns reported.
Read more →SMMT▲ +5%on this news
Summit Therapeutics to Present at Upcoming March 2026 Investor Conferences
Summit Therapeutics Inc. will participate in three investor conferences in March 2026. The leadership team will engage in individual meetings and fireside chats. The company is advancing its investigational bispecific antibody, ivonescimab, which is currently in multiple Phase III trials targeting various cancers. The FDA has accepted a BLA for ivonescimab, with a PDUFA date set for November 2026.
Read more →SMMTSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025
Summit Therapeutics has reported its financial results and operational updates for Q4 and the year ending December 31, 2025. The company is advancing its investigational bispecific antibody, ivonescimab, through multiple Phase III trials, with the FDA accepting a BLA filing. Key milestones include ongoing studies in various cancer types and a planned earnings call.
Read more →SMMTSummit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026
Summit Therapeutics will host a conference call on February 23, 2026, to discuss its fourth quarter and full year 2025 financial results along with an operational update. The call will be accessible via a live webcast on the company's website. Summit is dedicated to developing therapies aimed at addressing significant medical needs.
Read more →SMMTSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 30, 2026
Summit Therapeutics announced the grant of inducement awards for options to purchase up to 257,368 shares of common stock to 20 new employees. These awards, approved by the Compensation Committee, are part of a strategy to attract talent under Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and an exercise price of $16.56 per share.
Read more →SMMTSummit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy
Summit Therapeutics announced that the FDA has accepted its Biologics License Application for ivonescimab, a bispecific antibody aimed at treating EGFR-mutated NSCLC post-TKI therapy. The application is based on positive results from the Phase III HARMONi trial. The FDA has set a PDUFA action date of November 14, 2026, for the review process.
Read more →SMMTSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 6, 2025
Summit Therapeutics announced the grant of inducement awards for options to purchase 67,483 shares of common stock to nine new employees. This grant, approved by the Compensation Committee, is part of a strategy to attract talent under Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and an exercise price of $17.25 per share.
Read more →SMMTSummit Therapeutics Raises $500 Million in Private Placement Fundraise Led by Leading Biopharma Institutional Investors & Insiders $500 Million in Gross & Net Proceeds Raised at Yesterday's Closing Price of $18.74 Miami,
Summit Therapeutics announced the successful raising of $500 million in a private placement of approximately 26.68 million shares at a price of $18.74 each. The investment included significant contributions from company executives and leading biopharma institutional investors. The capital raised will be directed towards advancing the clinical development of ivonescimab, a novel bispecific antibody, among other corporate needs. This fundraise indicates robust support for Summit's strategic initiatives and its focus on oncology.
Read more →SMMTSummit Therapeutics Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has initiated an investigation into Summit Therapeutics Inc. for possible securities fraud, following disappointing results from its Phase III clinical trial of ivonescimab. The drug, while showing reduced progression in some patients, did not achieve a statistically significant impact on overall survival. Consequently, Summit’s stock suffered a sharp decline of over 30% after the initial results were announced. Additional findings suggesting weaker performance in certain patient demographics further exacerbated the situation, leading to another decline in stock price.
Read more →SMMTSummit Therapeutics Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 24, 2025 Deadline to file Lead Plaintiff Motion.
The Portnoy Law Firm is notifying investors of Summit Therapeutics Inc. about a class action lawsuit relating to false statements made during the Class Period from March 17, 2022, to September 22, 2022. Investors are invited to contact the firm to recover losses associated with the alleged misleading information regarding the Pinnacle Study of poziotinib. The deadline for filing a lead plaintiff motion is September 24, 2025. The law firm offers complimentary case evaluations to those affected.
Read more →SMMTSummit Therapeutics Inc. Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm has initiated an investigation into Summit Therapeutics Inc. regarding potential securities fraud after the company reported disappointing results from its Phase III clinical trial of ivonescimab. The trial showed the drug reduced disease progression or death risk by 48% compared to chemotherapy, but failed to demonstrate a significant improvement in overall survival. Following this news, Summit's stock price declined by about 30.5%. Investors are encouraged to contact the firm to discuss their rights and options for recovery.
Read more →SMMT▲ +20.7%on this news· ran to +41% by day 1
Summit Therapeutics Raises $235 Million Fundraise Led by Insiders & Leading Biopharma Institutional Investors in a Private Placement $235 Million in Net Proceeds Raised at Yesterday s Closing Price of $22.70 Miami, Flori
Summit Therapeutics announced the successful completion of a $235 million private placement, selling approximately 10.35 million shares at a price of $22.70 each. This capital raise included significant participation from both insiders and institutional investors, reflecting strong confidence in the company. The proceeds will primarily support the clinical development of its investigational drug, ivonescimab, for conditions including non-small cell lung cancer and other types of cancers. The company plans to leverage data from upcoming presentations at ESMO to further its research efforts.
Read more →SMMTSummit Raises $200 Million; Also Expands License Territories for Ivonescimab $200 Million in Net Proceeds Raised at Premium to Previous Closing Price In Separate Transaction, Summit Expanded License Territories for Ivone
Summit Therapeutics Inc. has raised $200 million through the sale of shares at a premium price. The company also announced an expansion of its licensing agreements for the investigational drug ivonescimab to include Latin America, the Middle East, and Africa. This expansion adds to previously established territories, enhancing the potential reach of this novel cancer therapy. The funding will support the clinical development of ivonescimab, which is currently undergoing multiple Phase III trials, although it remains unapproved in key markets such as the US and Europe.
Read more →SMMTPresented by Dr. Li Zhang, ASCO 2024 Presented by Dr. Li Zhang, ASCO 2024 Presented by Dr. Li Zhang, ASCO 2024 Presented by Dr. Li Zhang, ASCO 2024 Presented by Dr. Li Zhang, ASCO 2024 Presented by Dr. Li Zhang, ASCO 202
The article primarily repeats the phrase 'Presented by Dr. Li Zhang, ASCO 2024' numerous times without providing any specific details or insights about the event. This lack of content results in a failure to convey meaningful news or analysis related to the presentation or the conference. Consequently, readers are left without any valuable information regarding advancements or discussions expected at ASCO 2024.
Read more →SMMTSummit Therapeutics Inc. Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 08, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit”) investors that the firm has initiated an investigation into
Read more →SMMTSUMMIT INVESTOR ALERT: Kaskela Law LLC Announces Stockholder Investigation of Summit Therapeutics Inc. (SMMT) and Encourages SMMT Investors to Contact the Firm
PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit”) on behalf of the Company’s investors. The investigation seeks to determine whether Summit issued false and misleading statements
Read more →SMMT▲ +194.3%on this news· ran to +399% by day 3
Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody
Summit Therapeutics has partnered with Akeso Inc. to in-license ivonescimab, a bispecific antibody aimed at treating non-small cell lung cancer (NSCLC). The partnership, valued at up to $5 billion, allows Summit to develop and commercialize the drug in major markets, while Akeso retains rights in other regions. Ivonescimab has shown promising clinical results, including a high overall response rate in patients with NSCLC.
Read more →SMMTSummit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors
Summit Therapeutics has appointed Dr. Alessandra Cesano to its Board of Directors, effective immediately. Dr. Cesano brings over 25 years of experience in oncology and has previously held leadership roles in various biopharmaceutical companies. Her expertise is expected to aid Summit in expanding its oncology pipeline and improving patient outcomes.
Read more →SMMTSummit Therapeutics Inc. Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2022
Summit Therapeutics Inc. has released its financial results for the third quarter and nine months ending September 30, 2022. The company highlighted its operational progress and commitment to developing therapies that improve quality of life. However, it also acknowledged uncertainties related to clinical trials and regulatory approvals that may impact future operations.
Read more →SMMTSummit Rehabilitation Opens New Outpatient Physical Therapy Clinic in Kirkland
Kirkland, Wash.,, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Summit Rehabilitation, a network partner of Physical Rehabilitation Network (PRN), a leading US-based, owner-operator of outpatient physical therapy clinics, today announced the grand opening of its first outpatient physical the
Read more →SMMT▼ -6.7%on this news
Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
Summit Therapeutics presented positive results from the Ri-CoDIFy trial at IDWeek 2022, demonstrating that ridinilazole significantly reduces the recurrence of C. difficile infections compared to vancomycin. The trial, involving over 600 patients, highlighted ridinilazole's ability to preserve gut microbiome diversity while effectively treating the infection. This research underscores the importance of developing antibiotics that do not promote resistance.
Read more →SMMTSummit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
Menlo Park, California, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) and its product candidate, ridinilazole, will have an oral podium presentation and a poster presentation at IDWeek 2022. IDWeek is the joint annual
Read more →SMMTSummit Therapeutics Appoints Dr. Robert Booth, Renowned Executive and Scientific Leader, to its Board of Directors
Summit Therapeutics has appointed Dr. Robert Booth to its Board of Directors, effective immediately. Dr. Booth brings over 30 years of experience in the biopharmaceutical industry, particularly in oncology and drug development. His expertise is expected to significantly contribute to Summit's efforts in enhancing its product pipeline and addressing unmet medical needs.
Read more →SMMTSummit Therapeutics Inc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2022
Menlo Park, California, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the second quarter ended June 30, 2022. Financial Highlight
Read more →SMMTSummit Therapeutics Closes Fully-Subscribed $100 Million Rights Offering
Summit Therapeutics has successfully closed a fully-subscribed $100 million rights offering, selling approximately 103 million shares at $0.97 each. The net proceeds from the offering are roughly $99.9 million, which will support the company's ongoing mission to enhance human health. Key executives participated in the offering, reflecting their confidence in the company's future.
Read more →SMMTSummit Therapeutics’ Rights Offering Nearing Expiration Date
Summit Therapeutics Inc. is approaching the expiration date for its rights offering, set for August 8, 2022. The offering has a potential value of up to $100 million, but stockholders must act before the deadline to avoid losing their subscription rights. The company reports a strong financial position with over $73 million in cash and receivables.
Read more →SMMTSummit Therapeutics Appoints Dr. Maky Zanganeh as Co-CEO & President
Summit Therapeutics has appointed Dr. Maky Zanganeh as Co-CEO and President, effective immediately. Dr. Zanganeh, who previously served as COO, brings extensive leadership experience from her time at Pharmacyclics. The company is focused on expanding its pipeline and improving patient outcomes in oncology and infectious diseases under her leadership.
Read more →SMMTSummit Therapeutics Announces Commencement of $100 Million Rights Offering
Menlo Park, CA, July 18, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it has commenced its previously-announced rights offering of up to $100 million of the Company’s common stock. The subscription rights will expire and have no value if
Read more →SMMTSummit Therapeutics Provides Update on Ridinilazole
Menlo Park, CA, July 14, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today provided an update with respect to the clinical development of ridinilazole, its lead Phase III product candidate for the treatment of patients with
Read more →SMMT▲ +8%on this news
Summit Therapeutics Announces $100 Million Rights Offering
Menlo Park, CA, June 22, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that the Company’s Board of Directors has approved a rights offering available to all holders of record of the Company’s common stock, par value $
Read more →SMMTSummit Therapeutics’ Upcoming Annual Shareholders’ Meeting
Menlo Park, CA, June 03, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) invites our shareholders and other interested parties to attend our Company’s Annual Shareholders’ Meeting, which will now be held virtually on Thursday, June 16, 2022, at 1:00 pm Eastern T
Read more →SMMTSummit Therapeutics Appoints Ankur Dhingra as Chief Financial Officer
Cambridge, MA, June 01, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Ankur Dhingra has been appointed as Chief Financial Officer, effective immediately. “We are in a pivotal time for Team Summit as we seek to expand our portfolio of pipel
Read more →SMMT▼ -8.9%on this news
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2022
Cambridge, MA, May 11, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the first quarter ended March 31, 2022. Note: A glossary of terms is
Read more →SMMT▲ +7.9%on this news· ran to +19% by day 3
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2021
Cambridge, MA, March 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the fourth quarter and year ended December 31, 2021. Note: A gl
Read more →SMMTSummit Therapeutics Announces Postponement of Its Planned Rights Offering
Cambridge, Massachusetts, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced the postponement of its previously announced rights offering to stockholders of record on February 4, 2022. The Company had previously
Read more →SMMTSummit Therapeutics Announces Rights Offering
Cambridge, Massachusetts, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that the Company’s Board of Directors has approved a rights offering available to all holders of record of the Company’s common stock, p
Read more →SMMTSummit Therapeutics Today Presents Its Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference
Cambridge, Massachusetts, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) reminds interested stakeholders that it will today present the Company’s vision and its intended future development pathways at the 40th Annual J.P. Mor
Read more →SMMTSummit Therapeutics to Present Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference
Cambridge, Massachusetts, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that it will present the Company’s vision and its intended future development pathways at the 40th Annual J.P. Morgan Healthcare Confere
Read more →SMMT▼ -48%on this news
Summit Therapeutics Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection
Cambridge, MA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced topline results for the Phase III Ri-CoDIFy study evaluating its investigational drug, ridinilazole, for the treatment of and Sustained Clinical Re
Read more →SMMTSummit Therapeutics Inc Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2021
Cambridge, Massachusetts, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the third quarter and nine months ended September 30,
Read more →SMMTSummit Therapeutics Bolsters Its Board of Directors with Seasoned Regulatory & Clinical Research Executive Dr. Urte Gayko Cambridge, Massachusetts - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Dr. Urte G
Bolsters Its Board of Directors with Regulatory & Clinical Research Executive Dr. Urte Gayko Cambridge, Massachusetts - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Dr. Urte Gayko, PhD, has been appointed to our Board of Directors, effective immediately. Dr. G
Read more →SMMTSummit Therapeutics Appoints Prominent Biotech Attorney and Advisor Kenneth A. Clark to Its Board of Directors Cambridge, Massachusetts - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Kenneth A. Clark, JD,
Summit Therapeutics Appoints Prominent Biotech Attorney and Advisor Kenneth A. Clark to Its Board of Directors Cambridge, Massachusetts - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Kenneth A. Clark, JD, has been appointed to our Board of Directors, effective
Read more →SMMTSummit Therapeutics Presents Further Breakthrough Insights Surrounding the Novel Mechanism of Action for its Investigational Drug Ridinilazole During IDWeek 2021
Cambridge, Massachusetts, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) is today displaying an important ePoster at IDWeek 2021. IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Socie
Read more →SMMTSummit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended Cambridge, Massachusetts, August 11, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and p
Read more →SMMTSummit Therapeutics Provides Update on Ri-CoDIFy Trials Cambridge, Massachusetts - Based on a thorough review of the design and enrollment status of two ongoing blinded Phase III Ri-CoDIFy trials, Summit Therapeutics Inc
Summit Therapeutics Provides Update on Ri-CoDIFy Trials Cambridge, Massachusetts - Based on a thorough review of the design and enrollment status of two ongoing blinded Phase III Ri-CoDIFy trials, Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it will combine its
Read more →SMMTSummit Therapeutics Presents Breakthrough Research Data from Phase II Studies, including Evidence Validating Microbiome Preservation, for its Investigational Drug Ridinilazole
Cambridge, MA, July 12, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) is today displaying three preeminent ePosters at the prestigious 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). Two ePosters bring
Read more →SMMTSummit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Rated ePoster
Cambridge, MA, July 01, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (the “Company”) today announced that members of our scientific team will present breakthrough research updates at the 31st European Congress of Clinical Microbiology & Infectious Diseases (EC
Read more →SMMTSummit Therapeutics set to join Russell 3000 Index
Cambridge, MA, June 08, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US markets open on June 28, according to a prelimi
Read more →SMMTSummit Therapeutics Announces Preclinical Candidate and Associated CARB-X Funding Support for the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae, a CDC Urgent Threat and WHO Critical Priority
Cambridge, MA, May 18, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today that it has selected a new preclinical candidate, SMT026738 (“SMT-738”), for development in the fight against multidrug resistant infections, specifically carbapenem-resistant Enterobacteriaceae
Read more →SMMTSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2021
Cambridge, MA, May 17, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2021. Note: A glossary of terms is included at the end of this document in order to
Read more →SMMTSummit Therapeutics Announces Closing of $75 Million Rights Offering
Cambridge, MA, May 12, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today the successful closing of its fully subscribed rights offering and the associated results. The rights offering resulted in the sale of 14,312,976 shares of the Company’s common stock, par value
Read more →SMMTSummit Therapeutics Inc. ( We,' Summit,' or the Company') Summit Therapeutics Announces Closing of $75 Million Rights Offering Cambridge, MA
Summit Therapeutics Inc. Summit Therapeutics Announces Closing of $75 Million Rights Offering Cambridge, MA, May 12, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today the successful closing of its fully subscribed rights offering and the associated results. The r
Read more →SMMTSummit Therapeutics Publishes Scientific Updates to Corporate Website
Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that we have updated the scientific and related content on our corporate website with respect to our investigational drug, ridinilazole, which is currently enrolling patients in its Phase 3 clini
Read more →SMMTSummit Therapeutics’ Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights Offering
Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Daylight Time on May 10, 2021 (the “Expiration Date”). Importantly, for stockholders whose
Read more →SMMTSummit Therapeutics Inc. ( We,' Summit,' or the Company') Summit Therapeutics' Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights Offering Cambridge, MA
Summit Therapeutics Inc. Summit Therapeutics' Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights Offering Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it is nearing the
Read more →SMMTTHE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY'S PROSPECTUS SUPPLEMENT DATED APRIL 21, 2021 (THE "PROSPECTUS SUPPLEMENT") AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS A
THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY'S PROSPECTUS SUPPLEMENT DATED APRIL 21, 2021 (THE "PROSPECTUS SUPPLEMENT") AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS AND PROSPECTUS SUPPLEMENT ARE AVAILABLE UPON REQUEST FROM B
Read more →SMMTSummit Therapeutics Announces Commencement of Rights Offering
Summit Therapeutics Inc. (‘Summit’ or the ‘Company’) Summit Therapeutics Announces Commencement of Rights Offering Cambridge, MA, April 21, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it has commenced its previously-announced rights offering of up to 14
Read more →SMMTSummit Therapeutics Inc. ( Summit' or the Company') Summit Therapeutics Announces Rights Offering Cambridge, MA
Summit Therapeutics Announces Cambridge, MA, March 26, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the Company's Board of Directors has approved a rights offering available to all holders of record of the Company's common stock, par value $0.01 (the "Co
Read more →SMMTSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2020
Summit Therapeutics Inc. (‘Summit’ or the ‘Company’) Cambridge, MA, March 17, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on its operational progress for the fourth quarter and full-year ended December 31, 2020. Not
Read more →SMMTSummit Therapeutics Inc. ( Summit,' the Company,' or the Group') Summit Therapeutics Appoints Dr. Mahkam ("Maky") Zanganeh as Chief Operating Officer Cambridge, MA
Summit Therapeutics Inc. ( Summit,' the Company,' Summit Therapeutics Appoints Dr. Mahkam ("Maky") Zanganeh as Chief Operating Officer Cambridge, MA, November 23, 2020 - Summit Therapeutics Inc. (NASDAQ: SMMT) announces that Dr. Mahkam "Maky" Zanganeh, DDS, MBA, has been app
Read more →SMMTSummit Therapeutics Appoints Dr. Mahkam (“Maky”) Zanganeh as Chief Operating Officer
Summit Therapeutics Inc. (‘Summit,’ the ‘Company,’ or the ‘Group’) Summit Therapeutics Appoints Dr. Mahkam (“Maky”) Zanganeh as Chief Operating Officer Cambridge, MA, November 23, 2020 – Summit Therapeutics Inc. (NASDAQ: SMMT) announces that Dr. Mahkam “Maky” Zanganeh, DDS, MB
Read more →SMMTSummit Therapeutics Inc. ( Summit', the Company' or the Group') Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended
Summit Therapeutics Inc. ( Summit', the Company' Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2020 Cambridge, MA, November 16, 2020 - Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its
Read more →SMMTSummit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2020
Summit Therapeutics Inc. (‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2020 Cambridge, MA, November 16, 2020 - Summit Therapeutics Inc. (NASDAQ: SMMT) to
Read more →SMMTSummit Announces Closing of Private Placement of $50 Million
Summit Therapeutics Inc. (“Summit” or the “Company”) Summit Announces Closing of Private Placement of $50 Million Cambridge, MA, November 6, 2020 – Summit (NASDAQ: SMMT) today announces that it has closed its previously announced private placement for a fundraising of $50 mil
Read more →SMMTSummit Therapeutics Inc. ("Summit" or the "Company") Summit Announces Closing of Private Placement of $50 Million Cambridge, MA
Summit Therapeutics Inc. ("Summit" or the "Company") Summit Announces Closing of Private Placement of $50 Million Cambridge, MA, November 6, 2020 - Summit (NASDAQ: SMMT) today announces that it has closed its previously announced private placement for a fundraising of $50 mil
Read more →SMMTSummit Announces Agreement For a Fundraising of approximately $50 Million
Summit Therapeutics Inc. (“Summit” or the “Company”) Summit Announces Agreement For a Fundraising of approximately $50 Million Cambridge, MA, October 2, 2020 – Summit (NASDAQ: SMMT) today announces that it has entered into a binding agreement with the Company’s Chief Executive
Read more →SMMTSummit Therapeutics Inc. ("Summit" or the "Company") Summit Announces Agreement For a Fundraising of approximately $50 Million Cambridge, MA
Summit Therapeutics Inc. ("Summit" or the "Company") Summit Announces Agreement For a Fundraising of approximately $50 Million Cambridge, MA, October 2, 2020 - Summit (NASDAQ: SMMT) today announces that it has entered into a binding agreement with the Company's Chief Execut
Read more →SMMTSummit Therapeutics Inc. ( Summit , the Company or the Group ) Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended
Summit Therapeutics Inc. ( Summit , the Company or the Group ) Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2020 Cambridge, MA, September 29, 2020 - Summit Therapeutics Inc. (NASDAQ: SMMT) today rep
Read more →SMMTSummit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2020
Summit Therapeutics Inc. (‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2020 Cambridge, MA, September 29, 2020 - Summit Therapeutics Inc. (NASDAQ: SMMT) today
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) Summit Therapeutics Announces U.K. Court Approval of Scheme; Expects to Complete Redomiciliation to Delaware, USA as of
Summit Therapeutics plc Summit Therapeutics Announces U.K. Court Approval of Scheme; Expects to Complete Redomiciliation to Delaware, USA as of Oxford, UK, and Cambridge, MA, US, September 17, 2020 Summit Therapeutics plc (NASDAQ: SMMT) led by billionaire investor Robert W. Du
Read more →SMMTSummit Announces Effectiveness of Scheme of Arrangement and Completion of Redomiciliation to Delaware, USA
Summit Therapeutics Inc. (“Summit” or the “Company”) Summit Announces Effectiveness of Scheme of Arrangement and Completion of Redomiciliation to Delaware, USA Cambridge, MA, September 18, 2020 – Summit (NASDAQ: SMMT) today announces the completion of the company’s redomicilia
Read more →SMMTSummit Therapeutics Announces U.K. Court Approval of Scheme
Summit Therapeutics plc (“Summit” or the “Company”) Summit Therapeutics Announces U.K. Court Approval of Scheme; Expects to Complete Redomiciliation to Delaware, USA as of September 18, 2020. Oxford, UK, and Cambridge, MA, US, September 17, 2020 – Summit Therapeutics plc (NASD
Read more →SMMTSummit Announces Results of Court Meeting and General Meeting
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Results of Court Meeting and General Meeting Oxford, UK, and Cambridge, MA, US, August 19, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today announces that at a Court convened meeting of shareholders and at
Read more →SMMTTHIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. THIS DOCUMENT INCLUDES A PROPOSAL WHICH, IF IMPLEMENTED, WILL RESULT IN THE DELISTING OF THE AMERICAN DEPOSITARY SHARES, EACH REPRESENTING FIVE ORDINARY S
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. THIS DOCUMENT INCLUDES A PROPOSAL WHICH, IF IMPLEMENTED, WILL RESULT IN THE DELISTING OF THE AMERICAN DEPOSITARY SHARES, EACH REPRESENTING FIVE ORDINARY SHARES IN SUMMIT THERAPEUTICS PLC (INCORPORATED IN ENGLAND
Read more →SMMTSummit Announces Intention to Redomicile its Holding Company to the United States
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Intention to Redomicile its Holding Company to the United States Oxford, UK, and Cambridge, MA, US, July 16, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today announces its intention to relocate the corpora
Read more →SMMTSummit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health Oxford, UK, and Cambridge, MA, US, July 13, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today announces the publication of data from the Pha
Read more →SMMTSummit Appoints Michael Donaldson as Chief Financial Officer
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Appoints Michael Donaldson as Chief Financial Officer Oxford, UK, and Cambridge, MA, US, June 8, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today announces that Mr. Michael Donaldson has been appointed as Chief Fina
Read more →SMMTSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter and Three Months Ended March 31, 2020
Summit Therapeutics plc (‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter and Three Months Ended March 31, 2020 Oxford, UK, and Cambridge, MA, US, June 2, 2020 - Summit Therapeutics plc (NASDAQ
Read more →SMMTSummit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational Progress
Summit Therapeutics plc (‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational Progress Oxford, UK, and Cambridge, MA, US, April 30, 2020 - Summit Therapeutics plc
Read more →SMMTSummit Therapeutics plc ( Summit , the Company or the Group ) Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended
Summit Therapeutics plc ( Summit , the Company or the Group ) Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational Progress Oxford, UK, and Cambridge, MA, US, April 30, 2020 - Summit Therapeutics plc (NA
Read more →SMMTSummit Appoints Robert W. Duggan as Chief Executive Officer
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Appoints Robert W. Duggan as Chief Executive Officer Oxford, UK, and Cambridge, MA, US, 14 April 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today announces that Mr Robert (Bob) Duggan has been appointed Chief Execut
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) Summit Appoints Robert W. Duggan as Chief Executive Officer Oxford, UK, and Cambridge, MA, US, 14 April 2020 Summit Therapeutics plc (NASDAQ: SMMT) today announces that M
Summit Therapeutics plc ( Summit or the Company ) Appoints Robert W. Duggan as Chief Executive Officer Oxford, UK, and Cambridge, MA, US, 14 April 2020 Summit Therapeutics plc (NASDAQ: SMMT) today announces that Mr Robert (Bob) Duggan has been appointed Chief Executive Office
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) Summit Appoints Robert W. Duggan as Executive Chairman Oxford, UK, and Cambridge, MA, US, 26 February 2020 Summit Therapeutics plc (NASDAQ: SMMT) today announces it has a
Summit Therapeutics plc ( Summit or the Company ) Appoints Robert W. Duggan as Executive Chairman Oxford, UK, and Cambridge, MA, US, 26 February 2020 Summit Therapeutics plc (NASDAQ: SMMT) today announces it has appointed Robert W. Duggan as Executive Chairman of the Board of
Read more →SMMTSummit Appoints Robert W. Duggan as Executive Chairman
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Appoints Robert W. Duggan as Executive Chairman Oxford, UK, and Cambridge, MA, US, 26 February 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today announces it has appointed Robert W. Duggan as Executive Chairman of th
Read more →SMMTSummit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma Milestone Based on Achievement of Patient Enrolment Target in Phase 3 Clinical Trials of Ridinilazole Oxford, UK, and Cambridge, MA, US, 6 February
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma Milestone Based on Achievement of Patient Enrolment Target in Phase 3 Clinical Trials of Ridi
Summit Therapeutics plc ( Summit or the Company ) Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma Oxford, UK, and Cambridge, MA, US, 6 February 2020 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced that it achieved the first milestone un
Read more →SMMTSummit Therapeutics to Present at the 2020 BIO CEO & Investor Conference
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference Oxford, UK, and Cambridge, MA, US, 4 February 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Mr Glyn Edwards, Chief Executive O
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) Summit Announces Management Update Oxford, UK, and Cambridge, MA, US, 24 January 2020 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announces that Dr David Robl
Summit Therapeutics plc ( Summit or the Company ) Announces Management Update Oxford, UK, and Cambridge, MA, US, 24 January 2020 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announces that Dr David Roblin has resigned as Chief Operating Officer, Chief Medical Offic
Read more →SMMTSummit Announces Management Update
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Management Update Oxford, UK, and Cambridge, MA, US, 24 January 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announces that Dr David Roblin has resigned as Chief Operating Officer, Chief Med
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work Total Committed BARDA Funding Increased to $62.4 Million Total A
Summit Therapeutics plc ( Summit or the Company ) Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work Oxford, UK, and Cambridge, MA, US, 23 January 2020 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism
Read more →SMMTSummit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work Total Committed BARDA Funding Increased to $62.4 Million Total Award Increased to up to $72.5 Million Oxford, UK, and
Read more →SMMTSummit Therapeutics Launches Online Resource for Patients with C. difficile Infection
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Launches Online Resource for Patients with C. difficile Infection Oxford, UK, and Cambridge, MA, US, 7 January 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today launched www.ricodify.com, an o
Read more →SMMTSummit Therapeutics plc ( Summit Therapeutics or the Company ) Completion of $50 million Subscription and Placing and Directorate Changes Oxford, UK, and Cambridge, MA, US, 24 December 2019 - Summit Therapeutics (AIM: SU
Summit Therapeutics plc ( Summit Therapeutics or the Company ) Completion of $50 million Subscription and Placing and Directorate Changes Oxford, UK, and Cambridge, MA, US, 24 December 2019 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, an
Read more →SMMTSummit Therapeutics plc ( Summit Therapeutics or the Company ) Result of General Meeting, Admission of Fundraising Shares and Directorate Changes Oxford, UK, and Cambridge, MA, US, 23 December 2019 Summit Therapeutics (A
Summit Therapeutics plc ( Summit Therapeutics or the Company ) Result of General Meeting, Admission of Fundraising Shares and Directorate Changes Oxford, UK, and Cambridge, MA, US, 23 December 2019 Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovati
Read more →SMMTSummit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 October 2019
Summit Therapeutics plc (‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 October 2019 Oxford, UK, and Cambridge, MA, US, 17 December 2019 - Summit Therapeutics plc (NA
Read more →SMMTTHIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this Document or what action you should take, you should immediately consult your stockbroker, bank manager,
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this Document or what action you should take, you should immediately consult your stockbroker, bank manager, solicitor or other independent financial adviser authorise
Read more →SMMTTHIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, OR INTO ANY JURISDICTION
THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, OR INTO ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD B
Read more →SMMTSummit Announces a Proposed Subscription and Placing to Raise approximately $50.0 Million and Notice of General Meeting
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, OR INTO ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEM
Read more →SMMTSummit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress Oxford, UK, and Cambridge, MA, US, 6 November 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that managem
Read more →SMMTSummit Therapeutics Recognises C. difficile Awareness Month
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Recognises C. difficile Awareness Month Company to Highlight Potential of Phase 3 Precision Antibiotic Ridinilazole at the 7th Annual C. diff. Conference and Health EXPO Oxford, UK, and Cambridge, MA, US,
Read more →SMMTSummit Therapeutics to Present at the 2019 BIO Investor Forum
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Present at the 2019 BIO Investor Forum Oxford, UK, and Cambridge, MA, US, 16 October 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Mr Glyn Edwards, Chief Executive Officer, wil
Read more →SMMTSummit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection Data Presented at ID Week 2019 Oxford,
Read more →SMMTSummit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care Statistically Significant Improvements in Phy
Read more →SMMTSummit Therapeutics to Host R&D Day 7 October 2019
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Host R&D Day 7 October 2019 Oxford, UK, and Cambridge, MA, US, 25 September 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announces that it will host a research and development day for
Read more →SMMTSummit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019 Oxford, UK, and Cambridge, MA, US, 24 September 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) and collaborators will p
Read more →SMMTSummit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship Focus on Improving Patient Outcomes
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship Focus on Improving Patient Outcomes New Classes of Targeted Antibiotics Support Steward
Read more →SMMTSummit Presented In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotics at ASM/ESCMID Conference
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Presents In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotic at ASM/ESCMID Conference New Mechanism Antibiotic has Potential to Overcome Known Resistance Mechanisms Oxford, UK, and Cambridge, MA,
Read more →SMMTSummit Therapeutics to Participate in Upcoming Investor Conferences
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Participate in Upcoming Investor Conferences Oxford, UK, and Cambridge, MA, US, 4 September 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, ann
Read more →SMMTSummit Therapeutics to Present at the Canaccord Genuity Growth Conference
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Present at the Canaccord Genuity Growth Conference Oxford, UK, and Cambridge, MA, US, 1 August 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation,
Read more →SMMTSummit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress Oxford, UK, and Cambridge, MA, US, 17 July 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) t
Read more →SMMTSummit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia Proof of Concept Now Established in Animal Models Across Key Enterobacteriaceae Indications Pathogen-Targeted Approach Seeks
Read more →SMMTSummit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019 Oxford, UK, and Cambridge, MA, US, 20 June 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced that it wil
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) Result of Annual General Meeting Oxford, UK, and Cambridge, MA, US, 19 June 2019 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that all resolutions proposed
Summit Therapeutics plc ( Summit or the Company ) Annual General Meeting Oxford, UK, and Cambridge, MA, US, 19 June 2019 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that all resolutions proposed to shareholders at the Company s Annual General Meeting ( AGM ) h
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) Summit Announces BARDA Increases Award for Ridinilazole Clinical and Regulatory Development to up to $63.7 Million and Exercises Next Contract Option Summit Awarded $9.6M
Summit Therapeutics plc ( Summit or the Company ) Announces BARDA Increases Award for Ridinilazole Clinical and Regulatory Development to up to $63.7 Million and Exercises Next Contract Option Oxford, UK, and Cambridge, MA, US, 18 June 2019 Summit Therapeutics plc (NASDAQ: SMM
Read more →SMMTSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019
Summit Therapeutics plc (‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019 Oxford, UK, and Cambridge, MA, US, 12 June 2019 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM)
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) Publication of UK Annual Report and Notice of Annual General Meeting Oxford, UK, and Cambridge, MA, US, 14 May 2019 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), ann
Summit Therapeutics plc ( Summit or the Company ) of UK Annual Report and Notice of Annual General Meeting Oxford, UK, and Cambridge, MA, US, 14 May 2019 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), announces that its Annual Report and Accounts for the year ended 31 Jan
Read more →SMMTSummit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Presented In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019 DDS-04 Series Cures Enterobacteriaceae Infection in Animal Model Potential in Lung, Blo
Read more →SMMTSummit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae Data to be Presented in Oral Session at ECCMID 2019 Oxford, UK, and Cambridge, MA, US, 3 April 2019 – Summit Therapeutics plc (N
Read more →SMMTSummit Therapeutics to Present at H. C. Wainwright & Co. Global Life Sciences Conference
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Present at H. C. Wainwright & Co. Global Life Sciences Conference Oxford, UK, and Cambridge, MA, US, 2 April 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibioti
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) Award of Share Options Oxford, UK, and Cambridge, MA, US, 29 March 2019 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation
Summit Therapeutics plc ( Summit or the Company ) Oxford, UK, and Cambridge, MA, US, 29 March 2019 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces the annual grant of options over new ordinary shares of one penny no
Read more →SMMTSummit Therapeutics to Present at Upcoming Conferences
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Present at Upcoming Conferences Oxford, UK, and Cambridge, MA, US, 18 March 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces that mana
Read more →SMMTSummit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference N. Gonorrhoeae and ESKAPE Patho
Read more →SMMTSummit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data Data Highlight SMT-571’s Potential to Addres
Read more →SMMTSummit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection Trials Aim to Show Superiority of Ridinilazole Over Standard of Care Treatment Vancomycin Health Economic
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection Trials Aim to Show Superiority of Ridinilazole Over
Summit Therapeutics plc ( Summit or the Company ) First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection Oxford, UK, and Cambridge, MA, US, 13 February 2019 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new me
Read more →SMMTSummit Therapeutics to Present at the BIO CEO & Investor Conference
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Therapeutics to Present at the BIO CEO & Investor Conference Oxford, UK, and Cambridge, MA, US, 8 February 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, anno
Read more →SMMTSummit Therapeutics plc ( Summit Therapeutics or the Company ) Award of Restricted Stock Units Oxford, UK, and Cambridge, MA, US, 14 January 2019 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic in
Summit Therapeutics plc ( Summit Therapeutics or the Company ) Award of Restricted Stock Units Cambridge, MA, US, 14 January 2019 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces a grant of restricted stock units ( RSUs ) was made t
Read more →SMMTSummit Therapeutics plc ( Summit Therapeutics or the Company ) Completion of $25 million subscription Oxford, UK, and Cambridge, MA, US, 10 January 2019 Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiot
Summit Therapeutics plc ( Summit Therapeutics or the Company ) Completion of $25 million subscription UK, and Cambridge, MA, US, 10 January 2019 Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that the subscription to raise $25 milli
Read more →SMMTSummit Therapeutics plc ( Summit Therapeutics or the Company ) Result of General Meeting Oxford, UK, and Cambridge, MA, US, 4 January 2019 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovatio
Summit Therapeutics plc ( Summit Therapeutics or the Company ) Result of General Meeting Oxford, UK, and Cambridge, MA, US, 4 January 2019 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that at a general meeting of the Company he
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) Summit Therapeutics Announces Departure of Chief Financial Officer Oxford, UK, and Cambridge, MA, US, 17 December 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM)
Summit Therapeutics plc ( Summit or the Company ) Therapeutics Announces Departure of Chief Financial Officer Oxford, UK, and Cambridge, MA, US, 17 December 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, today announ
Read more →SMMTTHIS ANNOUNCEMENT (INCLUDING THE APPENDICES) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, OR INTO ANY JURISDICTI
THIS ANNOUNCEMENT (INCLUDING THE APPENDICES) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, OR INTO ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD
Read more →SMMTSummit Therapeutics Announces Departure of Chief Financial Officer
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Therapeutics Announces Departure of Chief Financial Officer Oxford, UK, and Cambridge, MA, US, 17 December 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, toda
Read more →SMMTSummit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 on 11 December 2018
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 on 11 December 2018 Oxford, UK, and Cambridge, MA, US, 6 December 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM:
Read more →SMMTSummit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week Preclinical Data on New Mechanism Antibiotic SMT-571 for the Treatment of Gonorrhoea are the Focus of an Oral
Read more →SMMTSummit Therapeutics to Participate in Jefferies 2018 London Healthcare Conference
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Therapeutics to Participate in Jefferies 2018 London Healthcare Conference Oxford, UK, and Cambridge, MA, US, 7 November 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic in
Read more →SMMTSummit Recognises C. difficile Awareness Month
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Recognises C. difficile Awareness Month Oxford, UK, and Cambridge, MA, US, 1 November 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, recognises C. difficile A
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) Award of Share Options Oxford, UK, and Cambridge, MA, US, 22 October 2018 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovati
Summit Therapeutics plc ( Summit or the Company ) Oxford, UK, and Cambridge, MA, US, 22 October 2018 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces the grant of options over new ordinary shares of one penny nominal
Read more →SMMTSummit Therapeutics to Participate in Upcoming Investor Events
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Therapeutics to Participate in Upcoming Investor Events Oxford, UK, and Cambridge, MA, US, 10 October 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that management will participate in two upcoming
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) Surrender of Share Options Oxford, UK, and Cambridge, MA, US, 8 October 2018 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innov
Summit Therapeutics plc ( Summit or the Company ) Oxford, UK, and Cambridge, MA, US, 8 October 2018 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces that UK-based Executive Director and PDMRs, and employees have volu
Read more →SMMTSummit Highlights Phase 3-Ready Precision Antibiotic Ridinilazole at IDWeek 2018
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Highlights Phase 3-Ready Precision Antibiotic Ridinilazole at IDWeek 2018 Ridinilazole in Development to Treat C. difficile Infection and Reduce Recurrent Disease Oxford, UK, and Cambridge, MA, US, 3 October 2018 – Su
Read more →SMMTSummit to Highlight Potential of Precision Antibiotic Ridinilazole to Treat C. difficile Infection and Reduce Recurrent Disease at ID Week 2018
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit to Highlight Potential of Precision Antibiotic Ridinilazole to Treat C. difficile Infection and Reduce Recurrent Disease at ID Week 2018 Oxford, UK, and Cambridge, MA, US, 26 September 2018 – Summit Therapeutics plc (N
Read more →SMMTSummit Reports Financial Results for the Second Quarter Ended 31 July 2018 and Operational Progress
Summit Therapeutics plc (‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results for the Second Quarter and Half Year Ended 31 July 2018 and Operational Progress Oxford, UK, and Cambridge, MA, US, 20 September 2018 - Summit Therapeutics plc (NASDA
Read more →SMMTSummit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2018 on 20 September 2018
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2018 on 20 September 2018 Oxford, UK, and Cambridge, MA, US, 14 September 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: S
Read more →SMMTSummit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen Targets
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen Targets Discovery Enabled by Discuva Platform and Proprietary Bacterial Libraries Oxford, UK, and Cambridge, MA, US, 6 September 2018 – Summit
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) Summit Nominates New Mechanism Antibiotic SMT-571 as its Lead Clinical Candidate for the Treatment of Gonorrhoea SMT-571 Designed to Exploit Novel N. gonorrhoeae Target I
Summit Therapeutics plc ( Summit or the Company ) Nominates New Mechanism Antibiotic SMT-571 as its Lead Clinical Candidate for the Treatment of Gonorrhoea Oxford, UK, and Cambridge, MA, US, 5 September 2018 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new m
Read more →SMMTSummit Nominates New Mechanism Antibiotic SMT-571 as its Lead Clinical Candidate for the Treatment of Gonorrhoea
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Nominates New Mechanism Antibiotic SMT-571 as its Lead Clinical Candidate for the Treatment of Gonorrhoea SMT-571 Designed to Exploit Novel N. gonorrhoeae Target Identified by Discuva Platform Details Presented at ESC
Read more →SMMTSummit Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
Accessibility: Skip TopNav Summit Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference August 29, 2018 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit", or the "Company") Summit Therapeutics to P
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) Summit Awarded Additional $12 Million by BARDA for Phase 3 Development Programme of Ridinilazole for the Treatment of C. difficile Infection Brings Total Committed Fundin
Summit Therapeutics plc ( Summit or the Company ) Awarded Additional $12 Million by BARDA for Phase 3 Development Programme of Ridinilazole for the Treatment of C. difficile Oxford, UK, and Cambridge, MA, US, 16 August 2018 Summit Therapeutics plc (NASDAQ:SMMT, AIM:SUMM), a l
Read more →SMMTSummit Awarded Additional $12 Million by BARDA for Ridinilazole
Accessibility: Skip TopNav Summit Awarded Additional $12 Million by BARDA for Ridinilazole August 16, 2018 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit' or 'the Company') Summit Awarded Additional $12 Million by BARDA for Phase
Read more →SMMTSummit Therapeutics plc : Director/PDMR Shareholding
Accessibility: Skip TopNav Summit Therapeutics plc : Director/PDMR Shareholding July 19, 2018 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit' or the 'Company') Exercise of Restricted Stock Units and Director Dealings Oxford, UK,
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) Director / PDMR Share Dealing Oxford, UK, Cambridge, MA, US, 17 July 2018 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), announces that it was notified on 16 July 2
Summit Therapeutics plc ( Summit or the Company ) Oxford, UK, Cambridge, MA, US, 17 July 2018 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), announces that it was notified on 16 July 2018 that Dr Frank Armstrong, Summit s Non-Executive Chairman, purchased 25,000 ordinary
Read more →SMMTSummit Therapeutics plc ( Summit , the Company , or the Group ) Director / PDMR Share Dealing Oxford, UK, Cambridge, MA, US, 16 July - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), announces that it was notified on
Summit Therapeutics plc ( Summit , the Company , or the Group ) Director / PDMR Share Dealing Oxford, UK, Cambridge, MA, US, 16 July - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), announces that it was notified on 13 July 2018 that Glyn Edwards, Summit s Chief Executive
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) Summit Awarded up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics Non-Dilutive Funding Could Support Development through Complet
Summit Therapeutics plc ( Summit or the Company ) Awarded up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics Oxford, UK, and Cambridge, MA, US, 10 July 2018 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces it has been award
Read more →SMMTSummit Awarded up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics
Summit Therapeutics plc (‘Summit’ or the “’Company’) Summit Awarded up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics Non-Dilutive Funding Could Support Development through Completion of a Phase 1 Clinical Trial Oxford, UK, and Cambr
Read more →SMMTSummit Therapeutics plc : Holding(s) in Company
Accessibility: Skip TopNav Summit Therapeutics plc : Holding(s) in Company July 02, 2018 12:48 ET Summit Therapeutics plc Summit Therapeutics plc TR-1: Standard form for notification of major holdings 1a. Identity of the issuer or the underlying issuer of existing shares to
Read more →SMMTSummit Therapeutics plc ( Summit , or the Company ) Summit Announces PhaseOut DMD Did Not Meet Primary Endpoint Ezutromid Development to be Discontinued Summit to Focus on Advancing its Pipeline of New Mechanism Antibiot
Summit Therapeutics plc ( Summit , or the Company ) Announces PhaseOut DMD Did Not Meet Primary Endpoint Oxford, UK, and Cambridge, MA, US, 27 June 2018 Summit Therapeutics plc (AIM:SUMM, NASDAQ:SMMT) today announces PhaseOut DMD has not met its primary or secondary endpoints
Read more →SMMTSummit Announces PhaseOut DMD Did Not Meet Primary Endpoint
Ezutromid Development to be Discontinued Summit to Focus on Advancing its Pipeline of New Mechanism Antibiotics Conference Call Scheduled for 8:00am EDT / 1:00pm BST OXFORD, United Kingdom and CAMBRIDGE, Mass., June 27, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUM
Read more →SMMTSummit Therapeutics Announces PhaseOut DMD Did Not Meet Primary Endpoint
Accessibility: Skip TopNav Summit Therapeutics Announces PhaseOut DMD Did Not Meet Primary Endpoint June 27, 2018 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit', or 'the Company') Summit Announces PhaseOut DMD Did Not Meet Primar
Read more →SMMTSummit Therapeutics to Present at the JMP Securities Life Sciences Conference
Accessibility: Skip TopNav Summit Therapeutics to Present at the JMP Securities Life Sciences Conference June 15, 2018 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit", or the "Company") Summit Therapeutics to Present at the JMP Se
Read more →SMMTSummit Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018
Highlights the Power of the Discuva Platform to Identify Novel Antibiotic Targets OXFORD, United Kingdom and CAMBRIDGE, Mass., June 11, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces the discovery of a second novel target to kill the bacteria
Read more →SMMTSummit Therapeutics Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018
Accessibility: Skip TopNav Summit Therapeutics Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018 June 11, 2018 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") Summit Unveils Second Novel Target for G
Read more →SMMTSummit Therapeutics plc : Result of AGM
Accessibility: Skip TopNav Summit Therapeutics plc : Result of AGM June 07, 2018 07:45 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit' or the "'Company') Result of Annual General Meeting Oxford, UK, and Cambridge, MA, US, 7 June 2018 -
Read more →SMMTSummit Therapeutics plc : 1st Quarter Results
Accessibility: Skip TopNav Summit Therapeutics plc : 1st Quarter Results June 05, 2018 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') Summit Therapeutics Reports Financial Results for the First Quar
Read more →SMMTSummit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2018 and Operational Progress
OXFORD, United Kingdom and CAMBRIDGE, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) today reports its financial results for the first quarter ended 30 April 2018 and provides an update on operational progress. Mr Glyn Edwards, Chief Ex
Read more →SMMTSummit Therapeutics plc : Notice of 1st Quarter Results
Accessibility: Skip TopNav Summit Therapeutics plc : Notice of 1st Quarter Results June 01, 2018 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit", or the "Company") Summit Therapeutics Provides Notice of Financial Results for the F
Read more →SMMTSummit Therapeutics Provides Notice of Financial Results for the First Quarter Ended 30 April 2018
OXFORD, United Kingdom and CAMBRIDGE, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT) will announce its financial results for the first quarter ended 30 April 2018 on 5 June 2018. About Summit Therapeutics Summit is a biopharmaceutical
Read more →SMMTDISCUVA LIMITED Index to Financial Statements Statement of Financial Position as at
Statement of Financial Position as at December 23, 2017 3 Statement of Comprehensive Income for the period ended December 23, 2017 4 Statement of Cash Flows for the period ended December 23, 2017 5 Statement of Changes in Equity for the period ended December 23, 2017 6
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) PUBLICATION OF UK ANNUAL REPORT AND NOTICE OF ANNUAL GENERAL MEETING Oxford, UK, and Cambridge, MA, US, 3 May 2018 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), anno
Summit Therapeutics plc ( Summit or the Company ) OF UK ANNUAL REPORT AND NOTICE OF ANNUAL GENERAL MEETING Oxford, UK, and Cambridge, MA, US, 3 May 2018 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), announces that its Annual Report and Accounts for the year ended 31 Janu
Read more →SMMTSummit Therapeutics plc : Notice of AGM
Accessibility: Skip TopNav Summit Therapeutics plc : Notice of AGM May 03, 2018 05:15 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") Publication of UK Annual Report and Notice of Annual General Meeting Oxford, UK, an
Read more →SMMTSummit Therapeutics plc : Total voting rights
Accessibility: Skip TopNav Summit Therapeutics plc : Total voting rights May 01, 2018 06:30 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") Oxford, UK, and Cambridge, MA, US, 1 May 2018 - Summit Therapeutics plc (NASDA
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) Award of Share Options and Restricted Stock Units Oxford, UK, and Cambridge, MA, US, 23 April 2018 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), announces that the
Summit Therapeutics plc ( Summit or the Company ) Share Options and Restricted Stock Units Oxford, UK, and Cambridge, MA, US, 23 April 2018 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), announces that the following options over new ordinary shares of one penny nominal
Read more →SMMTSummit Therapeutics plc : Grant of Share Options and RSUs
Accessibility: Skip TopNav Summit Therapeutics plc : Grant of Share Options and RSUs April 23, 2018 06:45 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit' or the 'Company') Award of Share Options and Restricted Stock Units Oxford, UK, a
Read more →SMMTSummit Highlights Discovery of New Mechanism Antibiotics for the Treatment of Gonorrhoea at ECCMID 2018
Accessibility: Skip TopNav Summit Highlights Discovery of New Mechanism Antibiotics for the Treatment of Gonorrhoea at ECCMID 2018 April 23, 2018 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") Summit Highlights
Read more →SMMTSummit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late-Breaking Presentation at ECCMID 2018
OXFORD, United Kingdom and CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces it highlighted the discovery of new mechanism antibiotic candidates for the treatment of gonorrhoea in a late-breaking presentation at the 28
Read more →SMMTSummit Presents New 24-Week Analyses from PhaseOut DMD at the 2018 AAN Conference
Accessibility: Skip TopNav Summit Presents New 24-Week Analyses from PhaseOut DMD at the 2018 AAN Conference April 20, 2018 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit', or 'the Company') Summit Presents New 24-Week Analyses fr
Read more →SMMTSummit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial
Accessibility: Skip TopNav Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial April 19, 2018 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") Summit Completes Dosing of Ezutromid in PhaseOut DMD C
Read more →SMMTSummit Therapeutics Files US Annual Report on Form 20F
Accessibility: Skip TopNav Summit Therapeutics Files US Annual Report on Form 20F April 13, 2018 09:45 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit", or the "Company") Summit Therapeutics Files US Annual Report on Form 20-F Oxford, U
Read more →SMMTSummit Therapeutics plc ( Summit , the Company or the Group ) Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2018 and Operational Progress Conference Call Today at 1
Summit Therapeutics plc ( Summit , the Company or the Group ) Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2018 and Operational Progress Oxford, UK, and Cambridge, MA, US, 11 April 2018 Summit Therapeutics plc (NASDAQ:
Read more →SMMTSummit Therapeutics Reports Financial Results for the Fiscal Year Ended 31 January 2018
Accessibility: Skip TopNav Summit Therapeutics Reports Financial Results for the Fiscal Year Ended 31 January 2018 April 11, 2018 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') Summit Therapeutics R
Read more →SMMTSummit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2018
OXFORD, United Kingdom and CAMBRIDGE, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT) will announce its financial results for the fourth quarter and fiscal year ended 31 January 2018 on 11 April 2018. Summit will host a conference call
Read more →SMMTSummit Therapeutics plc : Notice of Results
Accessibility: Skip TopNav Summit Therapeutics plc : Notice of Results April 09, 2018 10:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit", the "Company", or the "Group") Summit Therapeutics Provides Notice of Financial Results for the
Read more →SMMTSummit Therapeutics plc : Block listing Interim Review
Accessibility: Skip TopNav Summit Therapeutics plc : Block listing Interim Review April 06, 2018 09:15 ET Summit Therapeutics plc Summit Therapeutics plc BLOCK LISTING SIX MONTHLY RETURN (Note: Italicised terms have the same meaning as given in the Listing Rules.) Name of
Read more →SMMTSummit Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
Accessibility: Skip TopNav Summit Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference April 05, 2018 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit", or the "Company") Summit Therapeutics to Present at t
Read more →SMMTSummit Therapeutics Selected for Emerging Science Presentation at the 2018 AAN Annual Meeting
Accessibility: Skip TopNav Summit Therapeutics Selected for Emerging Science Presentation at the 2018 AAN Annual Meeting March 28, 2018 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit", or the "Company") Summit Therapeutics Selecte
Read more →SMMTSummit Therapeutics Announces the Results of Placing and Issue of Equity
Accessibility: Skip TopNav Summit Therapeutics Announces the Results of Placing and Issue of Equity March 27, 2018 07:00 ET Summit Therapeutics plc Summit Therapeutics plc This announcement is not for release, publication or distribution, directly or indirectly, in or into t
Read more →SMMTTHIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION WHERE TO DO SO MIGHT CON
THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF LOCAL SECURITIES LAWS OR REGULATIONS
Read more →SMMTSummit Therapeutics Announces a Proposed Placing to Raise up to 15 Million
Accessibility: Skip TopNav Summit Therapeutics Announces a Proposed Placing to Raise up to £15 Million March 27, 2018 02:00 ET Summit Therapeutics plc Summit Therapeutics plc THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INT
Read more →SMMTSummit Highlights Scientific Rigour of its PhaseOut DMD Clinical Trial at MDA Clinical Conference
Accessibility: Skip TopNav Summit Highlights Scientific Rigour of its PhaseOut DMD Clinical Trial at MDA Clinical Conference March 14, 2018 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") Summit Highlights Scient
Read more →SMMTSummit's Infectious Diseases Technology Platform Yields Novel Antibiotics with Potential in Global Fight Against Gonorrhoea
Accessibility: Skip TopNav Summit's Infectious Diseases Technology Platform Yields Novel Antibiotics with Potential in Global Fight Against Gonorrhoea March 13, 2018 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company")
Read more →SMMTSummit Expands Enrolment in Phase 2 Clinical Trial to Include Planned Additional Group
Accessibility: Skip TopNav Summit Expands Enrolment in Phase 2 Clinical Trial to Include Planned Additional Group March 07, 2018 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") Summit Expands Enrolment in PhaseOu
Read more →SMMTSummit Expands Enrolment in PhaseOut DMD Phase 2 Clinical Trial to Include Planned Additional Group
Additional Group is Open to Patients Who Participated in Phase 1 Clinical Trials of Ezutromid Allows Summit to Gather Additional Safety and Efficacy Data from a Broader Patient Population OXFORD, United Kingdom, March 07, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ
Read more →SMMTSummit Therapeutics plc : Research Update
Accessibility: Skip TopNav Summit Therapeutics plc : Research Update February 26, 2018 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit', or 'the Company') SUMMIT ANNOUNCES NEW ANALYSIS SHOWING EZUTROMID SIGNIFICANTLY REDUCED MUSCLE
Read more →SMMTSummit Announces New Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation in Phase 2 Clinical Trial in DMD
MRS-T2 Data Provide Evidence of Early Impact of Ezutromid on Downstream Muscle Health Data Build on Positive Biopsy Findings that Showed Significant Decrease in Muscle Damage OXFORD, United Kingdom, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SU
Read more →SMMTSummit Therapeutics plc ( Summit , or the Company ) SUMMIT ANNOUNCES NEW ANALYSIS SHOWING EZUTROMID SIGNIFICANTLY REDUCED MUSCLE INFLAMMATION IN PHASE 2 CLINICAL TRIAL IN DMD MRS-T2 Data Provide Evidence of Early Impact
Summit Therapeutics plc ( Summit , or the Company ) ANNOUNCES NEW ANALYSIS SHOWING EZUTROMID SIGNIFICANTLY REDUCED MUSCLE INFLAMMATION IN PHASE 2 CLINICAL TRIAL IN DMD UK, 26 February 2018 Summit Therapeutics plc (NASDAQ:SMMT, AIM:SUMM) announces further positive findings from
Read more →SMMTSummit Therapeutics to Participate in 2018 BTIG Healthcare Conference
Accessibility: Skip TopNav Summit Therapeutics to Participate in 2018 BTIG Healthcare Conference February 23, 2018 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit", or the "Company") SUMMIT THERAPEUTICS TO PARTICIPATE IN 2018 BTIG
Read more →SMMTSummit Therapeutics plc : Interim 24-Week Data from PhaseOut DMD
Accessibility: Skip TopNav Summit Therapeutics plc : Interim 24-Week Data from PhaseOut DMD January 25, 2018 07:05 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit', or 'the Company') EZUTROMID SIGNIFICANTLY REDUCED MUSCLE DAMAGE IN DMD P
Read more →SMMTSummit Therapeutics plc ( Summit , or the Company ) EZUTROMID SIGNIFICANTLY REDUCED MUSCLE DAMAGE IN DMD PATIENTS IN 24-WEEK INTERIM DATA FROM SUMMIT S PhaseOut DMD CLINICAL TRIAL Increase in Utrophin Protein Expression
Summit Therapeutics plc ( Summit , or the Company ) SIGNIFICANTLY REDUCED MUSCLE DAMAGE IN DMD PATIENTS IN 24-WEEK INTERIM DATA FROM SUMMIT S PhaseOut DMD CLINICAL TRIAL Oxford, UK, 25 January 2018 Summit Therapeutics plc (NASDAQ:SMMT, AIM:SUMM), the drug discovery and develo
Read more →SMMTSummit Therapeutics to Present at the Biotech Showcase
Accessibility: Skip TopNav Summit Therapeutics to Present at the Biotech Showcase January 09, 2018 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit", or the "Company") SUMMIT THERAPEUTICS TO PRESENT AT THE BIOTECH SHOWCASE Oxford,
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT OBTAINS INNOVATIVE ANTIBIOTIC DISCOVERY AND DEVELOPMENT PLATFORM THROUGH ACQUISITION OF DISCUVA LTD Positions Summit as a Leader in Research & Development of New C
Summit Therapeutics plc ( Summit or the Company ) OBTAINS INNOVATIVE ANTIBIOTIC DISCOVERY AND DEVELOPMENT PLATFORM THROUGH ACQUISITION OF DISCUVA LTD 23 December 2017 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therap
Read more →SMMTSummit Obtains Innovative Antibiotic Discovery and Development Platform Through Acquisition of Discuva Ltd.
Accessibility: Skip TopNav Summit Obtains Innovative Antibiotic Discovery and Development Platform Through Acquisition of Discuva Ltd. December 23, 2017 16:01 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit' or the 'Company') SUMMIT OBTA
Read more →SMMTSummit Enters Into Licence and Commercialisation Agreement With Eurofarma for Latin American Rights to Ridinilazole, Summit’s Precision Antibiotic in Development for the Treatment of CDI
Summit to receive $2.5 million upfront payment Up to $25 million in development, regulatory, pricing and initial sales milestones Summit retains commercial rights to ridinilazole in rest of the world OXFORD, United Kingdom, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics
Read more →SMMTSummit Enters Licence and Commercialisation Agreement with Eurofarma for Latin American Rights to Ridinilazole
Accessibility: Skip TopNav Summit Enters Licence and Commercialisation Agreement with Eurofarma for Latin American Rights to Ridinilazole December 21, 2017 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT E
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT ENTERS INTO LICENCE AND COMMERCIALISATION AGREEMENT WITH EUROFARMA FOR LATIN AMERICAN RIGHTS TO RIDINILAZOLE, SUMMIT S PRECISION ANTIBIOTIC IN DEVELOPMENT FOR THE
Summit Therapeutics plc ( Summit or the Company ) ENTERS INTO LICENCE AND COMMERCIALISATION AGREEMENT WITH EUROFARMA FOR LATIN AMERICAN RIGHTS TO RIDINILAZOLE, SUMMIT S PRECISION ANTIBIOTIC IN DEVELOPMENT FOR THE TREATMENT OF CDI 21 December 2017 Summit Therapeutics plc (NASDA
Read more →SMMTSummit Therapeutics Reports Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 and Operational Progress
OXFORD, United Kingdom, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM)(NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and C. difficile infection (‘CDI’), today reports its financial result
Read more →SMMTSummit, Santhera, Catabasis and Duchenne UK to Host DMD Awareness Day
Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day Liestal, Switzerland, Oxford, UK, Cambridge, Mass., 6 December 2017: Santhera Pharmaceuticals (SIX: SANN), Summit Therapeutics (NASDAQ: SMMT
Read more →SMMTSummit Therapeutics plc : 3rd Quarter Results
Accessibility: Skip TopNav Summit Therapeutics plc : 3rd Quarter Results December 06, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE THIRD
Read more →SMMTSummit Therapeutics plc ( Summit , the Company or the Group ) SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED 31 OCTOBER 2017 AND OPERATIONAL PROGRESS Oxford, UK, 6 December 2017
Summit Therapeutics plc Company or the Group ) SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED 31 OCTOBER 2017 AND OPERATIONAL PROGRESS Oxford, UK, 6 December 2017 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery
Read more →SMMTSummit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 on 6 December 2017
OXFORD, United Kingdom, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, will announce its financial results for
Read more →SMMTSummit Therapeutics plc : Notice of Third Quarter Results
Accessibility: Skip TopNav Summit Therapeutics plc : Notice of Third Quarter Results December 04, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR THE THIRD
Read more →SMMTSummit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients with DMD in PhaseOut DMD Clinical Trial
Accessibility: Skip TopNav Summit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients with DMD in PhaseOut DMD Clinical Trial November 20, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT COM
Read more →SMMTSummit Therapeutics plc : Miscellaneous
Accessibility: Skip TopNav Summit Therapeutics plc : Miscellaneous November 16, 2017 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT APPOINTS PANMURE GORDON AS JOINT BROKER Oxford, UK, 16 November 2017- S
Read more →SMMTSummit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at Action Duchenne
Accessibility: Skip TopNav Summit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at Action Duchenne November 09, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT HIGHLI
Read more →SMMTSummit Announces Signing of Revenue Sharing Agreement With the Wellcome Trust for CDI Antibiotic Ridinilazole
OXFORD, United Kingdom, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection (‘CDI’), announces it has entered into an
Read more →SMMTSummit Therapeutics Announces Revenue Sharing Agreement with Wellcome Trust
Accessibility: Skip TopNav Summit Therapeutics Announces Revenue Sharing Agreement with Wellcome Trust November 06, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT ANNOUNCES SIGNING OF REVENUE SHARING
Read more →SMMTSummit Therapeutics plc : Grant of share options
Accessibility: Skip TopNav Summit Therapeutics plc : Grant of share options October 25, 2017 09:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit' or the 'Company') GRANT OF SHARE OPTIONS TO DIRECTORS, PDMRS AND EMPLOYEES AND GRANT OF R
Read more →SMMTSummit Therapeutics plc : Block listing application
Accessibility: Skip TopNav Summit Therapeutics plc : Block listing application October 23, 2017 07:45 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") BLOCK LISTING APPLICATION Oxford, UK, 23 October 2017 - Summit Ther
Read more →SMMTSummit Highlights Microbiome Preservation During Ridinilazole Treatment at ID Week 2017
Accessibility: Skip TopNav Summit Highlights Microbiome Preservation During Ridinilazole Treatment at ID Week 2017 October 09, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit' or the 'Company') SUMMIT HIGHLIGHTS MICROBIOME PRE
Read more →SMMTSummit Therapeutics plc : Exercise of Options
Accessibility: Skip TopNav Summit Therapeutics plc : Exercise of Options October 05, 2017 11:25 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF SHARE OPTIONS Oxford, UK, 5 October 2017 - Summit Therapeutic
Read more →SMMTSummit Highlights DMD Biomarker Validation Data at 22nd WMS Congress
Accessibility: Skip TopNav Summit Highlights DMD Biomarker Validation Data at 22nd WMS Congress October 04, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit', or 'the Company') SUMMIT HIGHLIGHTS DMD BIOMARKER VALIDATION DATA AN
Read more →SMMTSummit Highlights DMD Biomarker Validation Data and Phase 2 Clinical Trial Baseline Characteristics in Presentations at 22nd WMS Congress
OXFORD, United Kingdom, Oct. 04, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, announces that a series of prese
Read more →SMMTSummit Therapeutics to Host R&D Day 11 October 2017
Accessibility: Skip TopNav Summit Therapeutics to Host R&D Day 11 October 2017 October 02, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit", or the "Company") SUMMIT THERAPEUTICS TO HOST R&D DAY 11 OCTOBER 2017 Oxford, UK, 2
Read more →SMMTSummit Therapeutics plc : Exercise of Share Options
Accessibility: Skip TopNav Summit Therapeutics plc : Exercise of Share Options September 29, 2017 13:20 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF SHARE OPTIONS Oxford, UK, 29 September 2017 - Summit
Read more →SMMTSummit Joins cTAP in Effort to Enhance Development of Utrophin Modulators and Other Treatments for DMD
Accessibility: Skip TopNav Summit Joins cTAP in Effort to Enhance Development of Utrophin Modulators and Other Treatments for DMD September 25, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit', or 'the Company') SUMMIT JOINS c
Read more →SMMTSummit Joins cTAP in Collaborative Effort to Enhance the Development of Utrophin Modulators and Other Treatments for Duchenne Muscular Dystrophy
OXFORD, United Kingdom, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT)(AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, today announces it has joined th
Read more →SMMTSummit Therapeutics Announces Closing of its ADS Public Offering Raising USD20.1M Before Expenses
Accessibility: Skip TopNav Summit Therapeutics Announces Closing of its ADS Public Offering Raising USD20.1M Before Expenses September 18, 2017 13:00 ET Summit Therapeutics plc Summit Therapeutics plc NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR I
Read more →SMMTNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Summit Therapeutics plc ( Summi
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Summit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS ANNOUNCES CLOSING
Read more →SMMTSummit Therapeutics Announces Exercise of Underwriters’ Over-Allotment Option
OXFORD, United Kingdom, Sept. 15, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, today announces that the underwriters of its und
Read more →SMMTSummit Announces Underwritten Public Offering of 1,459,000 ADSs to Raise USD17.5 Million Before Expenses
Accessibility: Skip TopNav Summit Announces Underwritten Public Offering of 1,459,000 ADSs to Raise USD17.5 Million Before Expenses September 14, 2017 02:00 ET Summit Therapeutics plc Summit Therapeutics plc NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART,
Read more →SMMTSummit Therapeutics Announces Pricing of Public Offering of 1,459,000 American Depositary Shares
OXFORD, United Kingdom, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces the pricing of its underwritten public
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF $15.0 MILLION OF AMERICAN DEPOSITARY SHARES Oxford, UK, 13 September 2017 Summit Therapeutics plc (NASDAQ: SMMT/
Summit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF $15.0 MILLION OF AMERICAN DEPOSITARY SHARES Oxford, UK, 13 September 2017 Summit Therapeutics plc (NASDAQ: SMMT/AIM: SUMM), the drug discovery and development company ad
Read more →SMMTSummit Therapeutics Announces Proposed Public Offering of $15.0 Million of American Depositary Shares
OXFORD, United Kingdom, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces that it is commencing an underwritten
Read more →SMMTSummit Therapeutics Awarded BARDA Contract Worth Up To $62M To Support Development of Ridinilazole for CDI
Accessibility: Skip TopNav Summit Therapeutics Awarded BARDA Contract Worth Up To $62M To Support Development of Ridinilazole for CDI September 11, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit Therapeutics', Summit', or the
Read more →SMMTSummit Awarded BARDA Contract Worth Up to $62 Million to Support the Development of Ridinilazole for the Treatment of C. difficile Infection
CAMBRIDGE, Mass. and OXFORD, United Kingdom, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection (‘CDI’), today announces that th
Read more →SMMTSummit Therapeutics plc ( Summit Therapeutics , Summit , or the Company ) SUMMIT AWARDED BARDA CONTRACT WORTH UP TO $62 MILLION TO SUPPORT THE DEVELOPMENT OF RIDINILAZOLE FOR THE TREATMENT OF C. DIFFICILE INFECTION Cambr
Summit Therapeutics plc ( Summit Therapeutics , Summit , or the Company ) SUMMIT AWARDED BARDA CONTRACT WORTH UP TO $62 MILLION TO SUPPORT THE DEVELOPMENT OF RIDINILAZOLE FOR THE TREATMENT OF C. DIFFICILE INFECTION Cambridge MA, Oxford, UK, 11 September 2017 Summit Therapeutic
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT ANNOUNCES POSITIVE TOP-LINE DATA FROM AN EXPLORATORY PHASE 2 CLINICAL TRIAL SUPPORTING RIDINILAZOLE AS A HIGHLY SELECTIVE ANTIBIOTIC FOR THE TREATMENT OF CDI Ridin
SUMMIT ANNOUNCES POSITIVE TOP-LINE DATA FROM AN EXPLORATORY PHASE 2 CLINICAL TRIAL SUPPORTING RIDINILAZOLE AS A HIGHLY SELECTIVE ANTIBIOTIC FOR THE TREATMENT OF CDI 5 September 2017 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company ad
Read more →SMMTSummit Therapeutics plc : Positive Top-line Phase 2 Results
Accessibility: Skip TopNav Summit Therapeutics plc : Positive Top-line Phase 2 Results September 05, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit' or the 'Company') SUMMIT ANNOUNCES POSITIVE TOP-LINE DATA FROM AN EXPLORATOR
Read more →SMMTSummit Announces Positive Top-Line Data From an Exploratory Phase 2 Clinical Trial Supporting Ridinilazole as a Highly Selective Antibiotic for the Treatment of CDI
OXFORD, United Kingdom, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection (‘CDI’), today announces positive top-li
Read more →SMMTSummit Therapeutics plc ( Summit , the Company or the Group ) SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER AND HALF YEAR ENDED 31 JULY 2017 AND OPERATIONAL PROGRESS Conference Call Scheduled for 1
Summit Therapeutics plc ( Summit , the Company or the Group ) SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER AND HALF YEAR ENDED 31 JULY 2017 AND OPERATIONAL PROGRESS Oxford, UK, 31 August 2017 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the dru
Read more →SMMTSummit Therapeutics plc : Half-yearly report
Accessibility: Skip TopNav Summit Therapeutics plc : Half-yearly report August 31, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE SECOND QU
Read more →SMMTSummit Therapeutics Reports Financial Results for the Second Quarter and Half Year Ended 31 July 2017 and Operational Progress
OXFORD, United Kingdom, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and C. difficile infection (‘CDI’), today reports its financial resul
Read more →SMMTSummit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2017 on 31 August 2017
OXFORD, United Kingdom, Aug. 25, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, will announce its financial results for
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) GRANT OF SHARE OPTIONS TO DIRECTORS, PDMRS AND EMPLOYEES AND GRANT OF RESTRICTED STOCK UNITS TO NON-EXECUTIVE DIRECTORS Oxford, UK, 19 July 2017 - Summit Therapeutics plc
Summit Therapeutics plc ( Summit or the Company ) SHARE OPTIONS TO DIRECTORS, PDMRS AND EMPLOYEES AND GRANT OF RESTRICTED STOCK UNITS TO NON-EXECUTIVE DIRECTORS Oxford, UK, 19 July 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development com
Read more →SMMTSummit Therapeutics plc : Grant of Share Options and Restricted Stock Units
Accessibility: Skip TopNav Summit Therapeutics plc : Grant of Share Options and Restricted Stock Units July 19, 2017 09:10 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit' or the 'Company') GRANT OF SHARE OPTIONS TO DIRECTORS, PDMRS AND
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) RESULT OF ANNUAL GENERAL MEETING Oxford, UK, 18 July 2017 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapie
Summit Therapeutics plc ( Summit or the Company ) ANNUAL GENERAL MEETING Oxford, UK, 18 July 2017 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infect
Read more →SMMTSummit Therapeutics plc : Grant of Share Options
Accessibility: Skip TopNav Summit Therapeutics plc : Grant of Share Options June 28, 2017 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") GRANT OF SHARE OPTIONS Oxford, UK, 28 June 2017 - Summit Therapeutics plc
Read more →SMMTSummit Presents Data from Phase 1 Clinical Programme of Ezutromid at the EPNS Congress
Accessibility: Skip TopNav Summit Presents Data from Phase 1 Clinical Programme of Ezutromid at the EPNS Congress June 22, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit', or 'the Company') SUMMIT PRESENTS DATA FROM PHASE 1 C
Read more →SMMTSummit Therapeutics to Participate in JMP Securities Life Sciences Conference
Accessibility: Skip TopNav Summit Therapeutics to Participate in JMP Securities Life Sciences Conference June 15, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit", or the "Company") SUMMIT THERAPEUTICS TO PARTICIPATE IN JMP SE
Read more →SMMTSummit Therapeutics plc ( Summit , the Company or the Group ) SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30 APRIL 2017 AND OPERATIONAL PROGRESS Oxford, UK, 14 June 2017 Summit Therapeutics
Summit Therapeutics plc ( Summit , the Company or the Group ) SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30 APRIL 2017 AND OPERATIONAL PROGRESS Oxford, UK, 14 June 2017 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and de
Read more →SMMTSummit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2017 and Operational Progress
OXFORD, United Kingdom, June 14, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and C. difficile infection (‘CDI’), today reports its unaudited finan
Read more →SMMTSummit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2017 on 14 June 2017
OXFORD, UK, June 13, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, will announce its financial results for the first qu
Read more →SMMTSummit Presents Positive New Preclinical Data on Novel CDI Antibiotic Ridinilazole at ASM Microbe 2017
Accessibility: Skip TopNav Summit Presents Positive New Preclinical Data on Novel CDI Antibiotic Ridinilazole at ASM Microbe 2017 June 05, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit' or the 'Company') SUMMIT PRESENTS POSI
Read more →SMMTSummit Announces Key Appointments to Strengthen Research & Development Team
Accessibility: Skip TopNav Summit Announces Key Appointments to Strengthen Research & Development Team May 23, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit' or the 'Company') SUMMIT ANNOUNCES KEY APPOINTMENTS TO STRENGTHEN
Read more →SMMTSummit Therapeutics plc ( Summit , or the Company ) SUMMIT COMPLETES ENROLMENT OF PhaseOut DMD, A PHASE 2 CLINICAL TRIAL OF EZUTROMID IN PATIENTS WITH DMD Summit to Receive $22 Million Milestone Payment Oxford, UK, 15 Ma
Summit Therapeutics plc ( Summit , or the Company ) COMPLETES ENROLMENT OF PhaseOut DMD, A PHASE 2 CLINICAL TRIAL OF EZUTROMID IN PATIENTS WITH DMD Oxford, UK, 15 May 2017 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing
Read more →SMMTSummit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMD
Accessibility: Skip TopNav Summit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMD May 15, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit', or 'the Company') SUMMIT COMPLETES ENR
Read more →SMMTSummit Therapeutics plc: Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases
Accessibility: Skip TopNav Summit Therapeutics plc: Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases May 02, 2017 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit', or the 'Company') PHASE 2 CoDIFy TRIAL RESULTS
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) PUBLICATION OF UK ANNUAL REPORT 2016/17 AND NOTICE OF ANNUAL GENERAL MEETING Oxford, UK, 25 April 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug disco
Summit Therapeutics plc ( Summit or the Company ) OF UK ANNUAL REPORT 2016/17 AND NOTICE OF ANNUAL GENERAL MEETING Oxford, UK, 25 April 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscul
Read more →SMMTSummit Therapeutics plc ( Summit , the Company , or the Group ) GRANT OF SHARE OPTIONS TO DIRECTORS/PDMRS Oxford, UK, 12 April 2017 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development co
Summit Therapeutics plc ( Summit , the Company , or the Group ) GRANT OF SHARE OPTIONS TO DIRECTORS/PDMRS UK, 12 April 2017 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clo
Read more →SMMTSummit Therapeutics File US Annual Report on Form 20-F
Accessibility: Skip TopNav Summit Therapeutics File US Annual Report on Form 20-F March 31, 2017 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit", or the "Company") SUMMIT THERAPEUTICS FILES US ANNUAL REPORT ON FORM 20-F Oxford, U
Read more →SMMTSummit Therapeutics plc : Change of Registered Office
Accessibility: Skip TopNav Summit Therapeutics plc : Change of Registered Office March 30, 2017 09:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit', 'the Company') SUMMIT ANNOUNCES CHANGE OF REGISTERED COMPANY ADDRESS Oxford, UK, 30
Read more →SMMTSummit Therapeutics to Present at the Needham Healthcare Conference
Accessibility: Skip TopNav Summit Therapeutics to Present at the Needham Healthcare Conference March 30, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit", the "Company", or the "Group") SUMMIT THERAPEUTICS TO PRESENT AT THE NE
Read more →SMMTSummit Therapeutics Reports 4th Quarter and Year End Financial Results and Operational Progress
Accessibility: Skip TopNav Summit Therapeutics Reports 4th Quarter and Year End Financial Results and Operational Progress March 29, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') SUMMIT THERAP
Read more →SMMTSummit Therapeutics plc ( Summit , the Company or the Group ) SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED 31 JANUARY 2017 AND OPERATIONAL PROGRESS Conference Call Today at 1
Summit Therapeutics plc ( Summit , the Company or the Group ) SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED 31 JANUARY 2017 AND OPERATIONAL PROGRESS Oxford, UK, 29 March 2017 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the d
Read more →SMMTSummit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational Progress
OXFORD, United Kingdom, March 29, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and C. difficile infection (‘CDI’), today reports its financial resu
Read more →SMMTSummit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017
OXFORD, United Kingdom, March 27, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, will be announcing its financial result
Read more →SMMTSummit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in Patients with DMD
Accessibility: Skip TopNav Summit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in Patients with DMD March 27, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit', 'the Company' or 'the Group') SUMMIT TO EXTEND ONGOI
Read more →SMMTSummit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference
Accessibility: Skip TopNav Summit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference March 15, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit", the "Company", or the "Group") SUMMIT THERAPEUTICS TO P
Read more →SMMTSummit Therapeutics Recognises Tenth Annual Rare Disease Day
Accessibility: Skip TopNav Summit Therapeutics Recognises Tenth Annual Rare Disease Day February 28, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit' or 'the Company') SUMMIT THERAPEUTICS RECOGNISES 10TH ANNUAL RARE DISEASE DA
Read more →SMMTSummit Therapeutics Recognises 10th Annual Rare Disease Day
OXFORD, United Kingdom, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, recognises the tenth annual Rare
Read more →SMMTSummit Therapeutics plc : Exercise of Warrants
Accessibility: Skip TopNav Summit Therapeutics plc : Exercise of Warrants February 23, 2017 07:15 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF WARRANTS Oxford, UK, 23 February 2017 - Summit Therapeutics
Read more →SMMTSummit Therapeutics to Participate in February Investor Conferences
Accessibility: Skip TopNav Summit Therapeutics to Participate in February Investor Conferences February 02, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit", the "Company", or the "Group") SUMMIT THERAPEUTICS TO PARTICIPATE IN
Read more →SMMTSummit Therapeutics plc ( Summit , the Company or the Group ) SUMMIT OUTLINES PHASE 3 PROGRAMME FOR NOVEL CDI ANTIBIOTIC RIDINILAZOLE FOLLOWING FDA AND EMA REGULATORY MEETINGS Oxford, UK, 1 February 2017 Summit Therapeut
Summit Therapeutics plc ( Summit , the Company or the Group ) SUMMIT OUTLINES PHASE 3 PROGRAMME FOR NOVEL CDI ANTIBIOTIC RIDINILAZOLE FOLLOWING FDA AND EMA REGULATORY MEETINGS Oxford, UK, 1 February 2017 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and
Read more →SMMTSummit Outline Phase 3 Programme for Novel CDI Antibiotic Ridinilazole
Accessibility: Skip TopNav Summit Outline Phase 3 Programme for Novel CDI Antibiotic Ridinilazole February 01, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') SUMMIT OUTLINES PHASE 3 PROGRAMME F
Read more →SMMTSummit Outlines Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Following FDA and EMA Regulatory Meetings
OXFORD, United Kingdom, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection (‘CDI’), today outlines its Phase 3 programme for
Read more →SMMTSummit Therapeutics plc ( Summit , Company or the Group ) SUMMIT APPOINTS DR DAVID ROBLIN AS CHIEF OPERATING OFFICER AND PRESIDENT OF RESEARCH & DEVELOPMENT Oxford, UK, 18 January 2017 Summit Therapeutics plc (AIM: SUMM,
Summit Therapeutics plc ( Summit , Company or the Group ) SUMMIT APPOINTS DR DAVID ROBLIN AS CHIEF OPERATING OFFICER AND PRESIDENT OF RESEARCH & DEVELOPMENT Oxford, UK, 18 January 2017 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development compan
Read more →SMMTSummit Appoints Dr David Roblin as Chief Operating Officer and President of Research & Development
Accessibility: Skip TopNav Summit Appoints Dr David Roblin as Chief Operating Officer and President of Research & Development January 18, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit', 'Company' or the 'Group') SUMMIT APPOI
Read more →SMMTSummit Chiropractic Offers Chiropractic Treatment for Victims of Car Accidents
ORLANDO, Fla., Jan. 15, 2017 (GLOBE NEWSWIRE) -- Most auto accident victims are unaware that they need to quickly address their car accident injuries. Chiropractic appointments should be made soon after a car accident as those that experience optimal results and receive useful in
Read more →SMMTSummit Therapeutics plc ( Summit , the Company or the Group ) SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED 31 OCTOBER 2016 AND OPERATIONAL PROGRESS Oxford, UK, 15 December 2016 Summit Therape
Summit Therapeutics plc ( Summit , the Company or the Group ) SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED 31 OCTOBER 2016 AND OPERATIONAL PROGRESS Oxford, UK, 15 December 2016 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery a
Read more →SMMTSummit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2016 and Operational Progress
OXFORD, United Kingdom, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and C. difficile infection (‘CDI’), today reports its financial resul
Read more →SMMTSummit Therapeutics to Report Financial Results for the Third Quarter Ended 31 October 2016 on 15 December 2016
OXFORD, United Kingdom, Dec. 13, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be announcing its financial results for the
Read more →SMMTSummit Enrols Patients in the United States Into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients With DMD
OXFORD, United Kingdom, Nov. 16, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, today announces that it has enro
Read more →SMMTSummit Enrolls Patients in the US into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid
Accessibility: Skip TopNav Summit Enrolls Patients in the US into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid November 16, 2016 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or "the Company") SUMMIT ENROLS PATIENTS IN TH
Read more →SMMTSummit Presents Preclinical DMD Data at 21st Congress of World Muscle Society
Accessibility: Skip TopNav Summit Presents Preclinical DMD Data at 21st Congress of World Muscle Society October 06, 2016 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or "the Company") SUMMIT THERAPEUTICS PRESENTS PRECLINICAL D
Read more →SMMTSummit Therapeutics Presents Preclinical DMD Data at the 21st International Congress of the World Muscle Society
Summit reports on development of new, automated biomarker tools to evaluate disease status of muscle biopsies OXFORD, United Kingdom, Oct. 06, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapie
Read more →SMMTSarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy Sarepta and Summit col
Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy Cambridge, MA, and Oxford, UK, 4 October 2016 Sarepta Therapeutics (NASDAQ: SRP
Read more →SMMTSummit Files Form 6-K on Licensing and Collaboration Agreement with Sarepta and Updated Cash Guidance
Accessibility: Skip TopNav Summit Files Form 6-K on Licensing and Collaboration Agreement with Sarepta and Updated Cash Guidance October 04, 2016 07:01 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT FILES FORM
Read more →SMMTSummit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement with Sarepta
Accessibility: Skip TopNav Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement with Sarepta October 04, 2016 07:01 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT TO HOST CONF
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM US FDA FOR EZUTROMID IN TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Oxford, UK, 27 September 2016 Summit Therapeutics
Summit Therapeutics plc ( Summit or the Company ) RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM US FDA FOR EZUTROMID IN TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Oxford, UK, 27 September 2016 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and developm
Read more →SMMTSummit Received Rare Pediatric Disease Designation from US FDA for Ezutromid in Treatment of DMD
Accessibility: Skip TopNav Summit Received Rare Pediatric Disease Designation from US FDA for Ezutromid in Treatment of DMD September 27, 2016 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or "the Company") SUMMIT RECEIVES RARE
Read more →SMMTSummit Receives Rare Pediatric Disease Designation From US FDA for Ezutromid in Treatment of Duchenne Muscular Dystrophy
OXFORD, United Kingdom, Sept. 27, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, today announces it has received
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT RECEIVES FAST TRACK DESIGNATION FROM US FDA FOR EZUTROMID IN THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Oxford, UK, 26 September 2016 Summit Therapeutics plc (NA
Summit Therapeutics plc ( Summit or the Company ) RECEIVES FAST TRACK DESIGNATION FROM US FDA FOR EZUTROMID IN THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Oxford, UK, 26 September 2016 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development comp
Read more →SMMTSummit Receives Fast Track Designation from US FDA for Ezutromid in the Treatment of DMD
Accessibility: Skip TopNav Summit Receives Fast Track Designation from US FDA for Ezutromid in the Treatment of DMD September 26, 2016 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or "the Company") SUMMIT RECEIVES FAST TRACK DE
Read more →SMMTSummit Launches Online Resource on Utrophin Modulation for the Duchenne Muscular Dystrophy Community
OXFORD, United Kingdom, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, today launches www.utrophintria
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED 31 JULY 2016 AND OPERATIONAL PROGRESS Conference call to be held 1:00pm BST / 8:00am EDT Oxford
Summit Therapeutics plc ( Summit or the Company ) THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED 31 JULY 2016 AND OPERATIONAL PROGRESS Oxford, UK, 8 September 2016 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development comp
Read more →SMMTSummit Therapeutics Reports Financial Results for the Second Quarter Ended 31 July 2016 and Operational Progress
Conference call to be held 1:00pm BST / 8:00am EDT OXFORD, United Kingdom, Sept. 08, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and C. difficile
Read more →SMMTSummit Therapeutics to Present at 18th Annual Rodman & Renshaw Global Investment Conference
Accessibility: Skip TopNav Summit Therapeutics to Present at 18th Annual Rodman & Renshaw Global Investment Conference September 07, 2016 07:00 ET Summit Therapeutics plc Summit Therapeutics plc SUMMIT THERAPEUTICS TO PRESENT AT 18TH ANNUAL RODMAN & RENSHAW GLOBAL INVESTMENT
Read more →SMMTSummit Therapeutics to Report Financial Results for the Second Quarter Ended 31 July 2016 on 8 September 2016
OXFORD, United Kingdom, Sept. 05, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be announcing its financial results for the
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT REPORTS POSITIVE PHASE 1 NEW FORMULATION DATA AND OUTLINES ROUTE TO MARKET STRATEGY FOR DMD CANDIDATE EZUTROMID New formulation of ezutromid achieved over a six-fo
Summit Therapeutics plc ( Summit or the Company ) REPORTS POSITIVE PHASE 1 NEW FORMULATION DATA AND OUTLINES ROUTE TO MARKET STRATEGY FOR DMD CANDIDATE EZUTROMID 9 August 2016 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advanci
Read more →SMMTSummit Reports Positive Phase 1 New Formulation Data and Outlines Route to Market Strategy for DMD Candidate Ezutromid
New formulation of ezutromid achieved over a six-fold increase in maximum plasma levels in patients Plans include incorporating new formulation into PhaseOut DMD trial OXFORD, United Kingdom, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), th
Read more →SMMTSummit Reports Positive Phase 1 Data and Outlines Route to Market Strategy for DMD Candidate Ezutromid
Accessibility: Skip TopNav Summit Reports Positive Phase 1 Data and Outlines Route to Market Strategy for DMD Candidate Ezutromid August 09, 2016 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or "the Company") SUMMIT REPORTS POS
Read more →SMMTSummit Therapeutics to Present at Canaccord Genuity Growth Conference
Accessibility: Skip TopNav Summit Therapeutics to Present at Canaccord Genuity Growth Conference August 05, 2016 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO PRESENT AT CANACCORD GENUITY
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) RESULT OF ANNUAL GENERAL MEETING Oxford, UK, 18 July 2016 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapie
Summit Therapeutics plc ( Summit or the Company ) ANNUAL GENERAL MEETING Oxford, UK, 18 July 2016 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ( DMD ) and Clostridium difficil
Read more →SMMTSummit Therapeutics plc : Award of Options
Accessibility: Skip TopNav Summit Therapeutics plc : Award of Options June 24, 2016 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") AWARD OF SHARE OPTIONS Oxford, UK, 24 June 2016 - Summit Therapeutics plc (AIM:
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) AWARD OF SHARE OPTIONS Oxford, UK, 24 June 2016 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duch
Summit Therapeutics plc ( Summit or the Company ) Oxford, UK, 24 June 2016 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces that on 23 June 20
Read more →SMMTSummit's Ridinilazole Preserves Microbiome During Treatment of C. Difficile Infection
Accessibility: Skip TopNav Summit's Ridinilazole Preserves Microbiome During Treatment of C. Difficile Infection June 21, 2016 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT'S RIDINILAZOLE PRESERVES MICRO
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) PUBLICATION OF UK ANNUAL REPORT AND NOTICE OF ANNUAL GENERAL MEETING Oxford, UK 17 June 201 6 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and de
Summit Therapeutics plc ( Summit or the Company ) OF UK ANNUAL REPORT AND NOTICE OF ANNUAL GENERAL MEETING Oxford, UK 17 June 2016 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy
Read more →SMMTSummit Therapeutics to Present at JMP Securities Life Sciences Conference
Accessibility: Skip TopNav Summit Therapeutics to Present at JMP Securities Life Sciences Conference June 16, 2016 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO PRESENT AT JMP SECURITIES
Read more →SMMTSummit Therapeutics to Host Utrophin R&D Day 15 June 2016
Accessibility: Skip TopNav Summit Therapeutics to Host Utrophin R&D Day 15 June 2016 June 08, 2016 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO HOST UTROPHIN R&D DAY 15 JUNE 2016 Oxford
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30 APRIL 2016 AND OPERATIONAL PROGRESS Oxford, UK, 2 June 2016 Summit Therapeutics plc (AIM: SUM
Summit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30 APRIL 2016 AND OPERATIONAL PROGRESS Oxford, UK, 2 June 2016 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development comp
Read more →SMMTSummit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2016 and Operational Progress
OXFORD, United Kingdom, June 02, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and C. difficile infection (‘CDI’), today reports its financial resul
Read more →SMMTSummit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2016 on 2 June 2016
OXFORD, United Kingdom, May 31, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its first quarter financial resu
Read more →SMMTSummit to Present Phase 2 CoDIFy Trial Data Highlighting Ridinilazole's Preservation of the Microbiome in CDI Patients at ASM Microbe 2016
OXFORD, United Kingdom, May 23, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection (‘CDI’), announces that the Company will p
Read more →SMMTSummit to Present Phase 2 CoDIFy Trial Data at ASM Microbe 2016
Accessibility: Skip TopNav Summit to Present Phase 2 CoDIFy Trial Data at ASM Microbe 2016 May 23, 2016 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT TO PRESENT PHASE 2 CoDIFy TRIAL DATA HIGHLIGHTING RID
Read more →SMMTSummit Therapeutics Reports Financial Results for Q4 and Fiscal Year Ended 31 January 2016
Accessibility: Skip TopNav Summit Therapeutics Reports Financial Results for Q4 and Fiscal Year Ended 31 January 2016 May 10, 2016 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS REPORTS FINAN
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED 31 JANUARY 2016 Oxford, UK, 10 May 2016 Summit Therapeutics plc (AIM: SUMM, NAS
Summit Therapeutics plc ( Summit or the Company ) THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED 31 JANUARY 2016 Oxford, UK, 10 May 2016 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancin
Read more →SMMTSummit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016
OXFORD, United Kingdom, May 06, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection (‘CDI’), will be announcing its financial
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT ANNOUNCES FURTHER US PATENT GRANTED FOR CDI ANTIBIOTIC RIDINILAZOLE Oxford, UK, 28 April 2016 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery
Summit Therapeutics plc ( Summit or the Company ) ANNOUNCES FURTHER US PATENT GRANTED FOR CDI ANTIBIOTIC RIDINILAZOLE Oxford, UK, 28 April 2016 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscu
Read more →SMMTSummit Announces Further US Patent Granted for CDI Antibiotic Ridinilazole
Accessibility: Skip TopNav Summit Announces Further US Patent Granted for CDI Antibiotic Ridinilazole April 28, 2016 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT ANNOUNCES FURTHER US PATENT GRANTED FOR
Read more →SMMTSummit's IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid
Accessibility: Skip TopNav Summit's IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid April 26, 2016 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or "the Company") SUMMIT'S IND CLEARED
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT S IND CLEARED BY FDA ALLOWING EXPANSION OF PhaseOut DMD, A PHASE 2 CLINICAL TRIAL OF EZUTROMID (SMT C1100), INTO THE US Enrolment of Patients with DMD in the US Ex
Summit Therapeutics plc ( Summit or the Company ) SUMMIT S IND CLEARED BY FDA ALLOWING EXPANSION OF PhaseOut DMD, A PHASE 2 CLINICAL TRIAL OF EZUTROMID (SMT C1100), INTO THE US Oxford, UK 26 April 2016 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) POSITIVE RESULTS FROM SUMMIT S PHASE 2 CoDIFy TRIAL HIGHLIGHT POTENTIAL OF RIDINILAZOLE IN THE TREATMENT OF C. DIFFICILE INFECTION Data Presented in Poster Session at 26
Summit Therapeutics plc ( Summit or the Company ) RESULTS FROM SUMMIT S PHASE 2 CoDIFy TRIAL HIGHLIGHT POTENTIAL OF RIDINILAZOLE IN THE TREATMENT OF C. DIFFICILE INFECTION Oxford, UK, 11 April 2016 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and deve
Read more →SMMTSummit Therapeutics to Present at 15th Annual Needham Healthcare Conference
Accessibility: Skip TopNav Summit Therapeutics to Present at 15th Annual Needham Healthcare Conference April 06, 2016 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO PRESENT AT 15TH ANNUAL
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT TO PRESENT ADDITIONAL DATA FROM PHASE 2 CoDIFy TRIAL SHOWING RIDINILAZOLE S STATISTICAL SUPERIORITY OVER VANCOMYCIN IN SUSTAINED CLINICAL RESPONSE WAS DRIVEN BY MA
Summit Therapeutics plc ( Summit or the Company ) PRESENT ADDITIONAL DATA FROM PHASE 2 CoDIFy TRIAL SHOWING RIDINILAZOLE S STATISTICAL SUPERIORITY OVER VANCOMYCIN IN SUSTAINED CLINICAL RESPONSE WAS DRIVEN BY MARKED REDUCTION IN RECURRENCE OF C. DIFFICILE INFECTION Oxford, UK,
Read more →SMMTSummit Reports Positive Interim Data From Ongoing Phase 1 Clinical Trial Testing a New Formulation of SMT C1100 in Patients With DMD
OXFORD, United Kingdom, March 30, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, announces positive interim data
Read more →SMMTSummit Reports Positive Interim Data from Phase 1 Testing a New Formulation of SMT C1100 in DMD Patients
Accessibility: Skip TopNav Summit Reports Positive Interim Data from Phase 1 Testing a New Formulation of SMT C1100 in DMD Patients March 30, 2016 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or "the Company") SUMMIT REPORTS PO
Read more →SMMTSUMMIT TO PRESENT ADDITIONAL DATA FROM PHASE 2 CoDIFy TRIAL FOR THE TREATMENT OF C. DIFFICILE INFECTION
Accessibility: Skip TopNav SUMMIT TO PRESENT ADDITIONAL DATA FROM PHASE 2 CoDIFy TRIAL FOR THE TREATMENT OF C. DIFFICILE INFECTION March 29, 2016 09:25 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or "the Company") SUMMIT TO PRESENT
Read more →SMMTMarch 2016 Dear Shareholder, Notification to shareholders regarding parent company financial statements: Adoption of Financial Reporting Standard ( FRS ) 101 Reduced Disclosure Framework The financial statements for the
Notification to shareholders regarding parent company financial statements: Adoption of Financial Reporting Standard ( FRS ) 101 Reduced Disclosure Framework The financial statements for the year ended 31 January 2015 of the individual entity, Summit Therapeutics plc (the Comp
Read more →SMMTSummit Therapeutics plc : Shareholder Notifications
Accessibility: Skip TopNav Summit Therapeutics plc : Shareholder Notifications March 22, 2016 05:30 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or "the Company") SHAREHOLDER NOTIFICATIONS Oxford, UK, 22 March 2016 - Summit Therapeu
Read more →SMMTSummit Announces Publication on Biomarkers to Quantify Utrophin and Regeneration of Muscle Fibres in DMD
Accessibility: Skip TopNav Summit Announces Publication on Biomarkers to Quantify Utrophin and Regeneration of Muscle Fibres in DMD March 15, 2016 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or "the Company") SUMMIT ANNOUNCES
Read more →SMMTSummit Announces Ridinilazole Preserves the Gut Microbiome of Patients With C. difficile Infection in Phase 2 Trial
OXFORD, United Kingdom, March 07, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection (‘CDI’), announces additional positive d
Read more →SMMTSummit Announce Ridinilazole Preserves the Gut Microbiome of Patients with C. difficile Infection
Accessibility: Skip TopNav Summit Announce Ridinilazole Preserves the Gut Microbiome of Patients with C. difficile Infection March 07, 2016 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or "the Company") SUMMIT ANNOUNCES RIDINIL
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT ANNOUNCES RIDINILAZOLE PRESERVES THE GUT MICROBIOME OF PATIENTS WITH C. DIFFICILE INFECTION IN PHASE 2 TRIAL Oxford, UK, 7 March 2016 Summit Therapeutics plc (NASD
Summit Therapeutics plc ( Summit or the Company ) ANNOUNCES RIDINILAZOLE PRESERVES THE GUT MICROBIOME OF PATIENTS WITH C. DIFFICILE INFECTION IN PHASE 2 TRIAL Oxford, UK, 7 March 2016 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development compan
Read more →SMMTSummit Therapeutics Supports Ninth Annual Rare Disease Day
Accessibility: Skip TopNav Summit Therapeutics Supports Ninth Annual Rare Disease Day February 29, 2016 07:35 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or "the Company") SUMMIT THERAPEUTICS SUPPORTS NINTH ANNUAL RARE DISEASE DAY
Read more →SMMTSummit Therapeutics Announces Publication of Preclinical Data Showing Ridinilazole Outperformed Standard of Care in Reducing C. Difficile Toxins That Drive Disease Symptoms
OXFORD, United Kingdom, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection (‘CDI’), announces the online publication
Read more →SMMTSummit Therapeutics to Participate in SunTrust Robinson Humphrey's 2016 Orphan Drug Day
Accessibility: Skip TopNav Summit Therapeutics to Participate in SunTrust Robinson Humphrey's 2016 Orphan Drug Day February 17, 2016 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO PARTICIP
Read more →SMMTSummit Therapeutics to Present at 18th Annual BIO CEO & Investor Conference
OXFORD, United Kingdom, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn Edwards, Chief Ex
Read more →SMMTSummit Therapeutics to Present at BIO CEO & Investor Conference
Accessibility: Skip TopNav Summit Therapeutics to Present at BIO CEO & Investor Conference February 03, 2016 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO PRESENT AT 18TH ANNUAL BIO CEO &
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS GRANTED KEY EUROPEAN PATENT FOR NOVEL ANTIBIOTIC RIDINILAZOLE FOR TREATMENT OF C. DIFFICILE INFECTION Oxford, UK, 19 January 2016 Summit Therapeutics
Summit Therapeutics plc ( Summit or the Company ) THERAPEUTICS GRANTED KEY EUROPEAN PATENT FOR NOVEL ANTIBIOTIC RIDINILAZOLE FOR TREATMENT OF C. DIFFICILE INFECTION UK, 19 January 2016 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development compan
Read more →SMMTSummit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial in DMD
Accessibility: Skip TopNav Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial in DMD January 21, 2016 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or "the Company") SUMMIT THERAP
Read more →SMMTSummit Therapeutics Granted Key European Patent for Novel C. difficile Antibiotic Ridinilazole
Accessibility: Skip TopNav Summit Therapeutics Granted Key European Patent for Novel C. difficile Antibiotic Ridinilazole January 19, 2016 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or "the Company") SUMMIT THERAPEUTICS GRANT
Read more →SMMTSummit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2015
Accessibility: Skip TopNav Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2015 December 17, 2015 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit' or the 'Company') SUMMIT THERAPEUTICS REPORTS F
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED 31 OCTOBER 2015 AND OPERATIONAL PROGRESS Oxford, UK, 17 December 2015 Summit Therapeutics plc (A
Summit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED 31 OCTOBER 2015 AND OPERATIONAL PROGRESS Oxford, UK, 17 December 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and developme
Read more →SMMTSummit Therapeutics to Report Financial Results for the Third Quarter Ended 31 October 2015 on 17 December 2015
OXFORD, United Kingdom, Dec. 14, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its third quarter financial res
Read more →SMMTSummit Therapeutics to Report Third Quarter 2015 Financial Results
Accessibility: Skip TopNav Summit Therapeutics to Report Third Quarter 2015 Financial Results December 14, 2015 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR
Read more →SMMTSummit Therapeutics to Participate in the JMP Securities DMD Forum
Accessibility: Skip TopNav Summit Therapeutics to Participate in the JMP Securities DMD Forum December 10, 2015 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO PARTICIPATE IN THE JMP SECURIT
Read more →SMMTSummit Therapeutics to Present at the 26th Annual Oppenheimer Healthcare Conference
Accessibility: Skip TopNav Summit Therapeutics to Present at the 26th Annual Oppenheimer Healthcare Conference December 03, 2015 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO PRESENT AT T
Read more →SMMTSummit Therapeutics Achieve First Milestone in Strategic Alliance with Oxford University
Accessibility: Skip TopNav Summit Therapeutics Achieve First Milestone in Strategic Alliance with Oxford University December 02, 2015 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or "the Company") SUMMIT THERAPEUTICS ANNOUNCES
Read more →SMMTSummit Therapeutics Announces First Milestone Achieved in Strategic Alliance With University of Oxford for Future Generation Utrophin Modulators for Treatment of DMD
OXFORD, United Kingdom, Dec. 2, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficile infection, announces the achievement of the
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS ANNOUNCES FIRST MILESTONE ACHIEVED IN STRATEGIC ALLIANCE WITH UNIVERSITY OF OXFORD FOR FUTURE GENERATION UTROPHIN MODULATORS FOR TREATMENT OF DMD Oxfo
Summit Therapeutics plc ( Summit or the Company ) THERAPEUTICS ANNOUNCES FIRST MILESTONE ACHIEVED IN STRATEGIC ALLIANCE WITH UNIVERSITY OF OXFORD FOR FUTURE GENERATION UTROPHIN MODULATORS FOR TREATMENT OF DMD Oxford, UK, 2 December 2015 Summit Therapeutics plc (NASDAQ: SMMT, A
Read more →SMMTSummit Therapeutics to Present at the Piper Jaffray Healthcare Conference
Accessibility: Skip TopNav Summit Therapeutics to Present at the Piper Jaffray Healthcare Conference November 25, 2015 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO PRESENT AT THE PIPER J
Read more →SMMTSummit Therapeutics Announces Novel Antibiotic Ridinilazole (SMT19969) Achieves Statistical Superiority Over Vancomycin in CoDIFy Phase 2 Clinical Trial for C. difficile Infection
Sustained Clinical Response Rates of 66.7% with Ridinilazole vs. 42.4% with Vancomycin Ridinilazole to Advance into Phase 3 Clinical Development Conference Call Scheduled for 1:00pm GMT / 8:00am EST OXFORD, United Kingdom, Nov. 23, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics
Read more →SMMTSummit Therapeutics Announces Positive Phase 2 Results of Ridinilazole for Treatment of C difficile Infection
Accessibility: Skip TopNav Summit Therapeutics Announces Positive Phase 2 Results of Ridinilazole for Treatment of C difficile Infection November 23, 2015 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit' or 'the Company') SUMMIT TH
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS ANNOUNCES NOVEL ANTIBIOTIC RIDINILAZOLE (SMT19969) ACHIEVES STATISTICAL SUPERIORITY OVER VANCOMYCIN IN CoDIFy PHASE 2 CLINICAL TRIAL FOR C. DIFFICILE
Summit Therapeutics plc ( Summit or the Company ) THERAPEUTICS ANNOUNCES NOVEL ANTIBIOTIC RIDINILAZOLE (SMT19969) ACHIEVES STATISTICAL SUPERIORITY OVER VANCOMYCIN IN CoDIFy PHASE 2 CLINICAL TRIAL FOR C. DIFFICILE INFECTION Oxford, UK, 23 November 2015 Summit Therapeutics plc
Read more →SMMTSummit Therapeutics plc : Director Declaration
Accessibility: Skip TopNav Summit Therapeutics plc : Director Declaration November 20, 2015 09:25 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") DIRECTOR DECLARATION Oxford, UK, 20 November 2015 - Summit Therapeutics
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS AND THE UNIVERSITY OF OXFORD ANNOUNCE MULTI-YEAR EXTENSION OF STRATEGIC ALLIANCE FOR DEVELOPMENT OF UTROPHIN MODULATORS FOR DMD Oxford, UK, 17 Novembe
Summit Therapeutics plc ( Summit or the Company ) THERAPEUTICS AND THE UNIVERSITY OF OXFORD ANNOUNCE MULTI-YEAR EXTENSION OF STRATEGIC ALLIANCE FOR DEVELOPMENT OF UTROPHIN MODULATORS FOR DMD Oxford, UK, 17 November 2015 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the dr
Read more →SMMTSummit Therapeutics and the University of Oxford Announce Multi-year Extension of Strategic Alliance for Development of Utrophin Modulators for DMD
Accessibility: Skip TopNav Summit Therapeutics and the University of Oxford Announce Multi-year Extension of Strategic Alliance for Development of Utrophin Modulators for DMD November 17, 2015 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc
Read more →SMMTSummit Therapeutics plc : Award of Share Options
Accessibility: Skip TopNav Summit Therapeutics plc : Award of Share Options October 15, 2015 10:14 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") AWARD OF SHARE OPTIONS Oxford, UK, 15 October 2015 - Summit Therapeuti
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS PRESENTS ADDITIONAL DATA FROM PHASE 1B MODIFIED DIET CLINICAL TRIAL OF SMT C1100 IN DMD PATIENTS AT WMS 10 of 12 Patients Achieved Plasma Concentratio
Summit Therapeutics plc ( Summit or the Company ) THERAPEUTICS PRESENTS ADDITIONAL DATA FROM PHASE 1B MODIFIED DIET CLINICAL TRIAL OF SMT C1100 IN DMD PATIENTS AT WMS Oxford, UK, 30 September 2015 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and develo
Read more →SMMTSummit Therapeutics Presents Additional Data from Phase 1b Modfied Diet Clinical Trial of SMT C1100 in DMD
Accessibility: Skip TopNav Summit Therapeutics Presents Additional Data from Phase 1b Modfied Diet Clinical Trial of SMT C1100 in DMD September 30, 2015 07:00 ET Summit Therapeutics plc Summit Therapeutics plc SUMMIT THERAPEUTICS PRESENTS ADDITIONAL DATA FROM PHASE 1B MODIFI
Read more →SMMTSummit Therapeutics to Present Phase 1b Clinical and Preclinical DMD Data at WMS Congress 2015
Accessibility: Skip TopNav Summit Therapeutics to Present Phase 1b Clinical and Preclinical DMD Data at WMS Congress 2015 September 24, 2015 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or "the Company") SUMMIT THERAPEUTICS TO
Read more →SMMTSummit Therapeutics Presents New Positive Preclinical Data on C. difficile Antibiotic SMT19969 at ICAAC 2015
Accessibility: Skip TopNav Summit Therapeutics Presents New Positive Preclinical Data on C. difficile Antibiotic SMT19969 at ICAAC 2015 September 18, 2015 08:30 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit' or 'the Company') SUMMIT TH
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS COMPLETES TARGETED ENROLMENT FOR SMT19969 PHASE 2 TRIAL FOR C. DIFFICILE INFECTION Oxford, UK, 10 September, 2015 Summit Therapeutics plc (AIM: SUMM,
Summit Therapeutics plc ( Summit or the Company ) THERAPEUTICS COMPLETES TARGETED ENROLMENT FOR SMT19969 PHASE 2 TRIAL FOR C. DIFFICILE INFECTION Oxford, UK, 10 September, 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advan
Read more →SMMTSummit Therapeutics Completes Targeted Enrolment for SMT19969 Phase 2 Trial for C. difficile Infection
Accessibility: Skip TopNav Summit Therapeutics Completes Targeted Enrolment for SMT19969 Phase 2 Trial for C. difficile Infection September 10, 2015 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit' or the 'Company') SUMMIT THERAPEU
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS APPOINTS RALF ROSSKAMP, MD, AS CHIEF MEDICAL OFFICER Oxford, UK, 2 September 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discover
Summit Therapeutics plc ( Summit or the Company ) THERAPEUTICS APPOINTS RALF ROSSKAMP, MD, AS CHIEF MEDICAL OFFICER Oxford, UK, 2 September 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne musc
Read more →SMMTSummit Therapeutics Appoints Ralf Rosskamp MD as Chief Medical Officer
Accessibility: Skip TopNav Summit Therapeutics Appoints Ralf Rosskamp MD as Chief Medical Officer September 02, 2015 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS APPOINTS RALF ROSSKAMP, MD,
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED 31 JULY 2015 AND OPERATIONAL PROGRESS Oxford, UK, 27 August 2015 Summit Therapeutics plc (AIM:
Summit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED 31 JULY 2015 AND OPERATIONAL PROGRESS Oxford, UK, 27 August 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development c
Read more →SMMTSummit Therapeutics Reports Financial Results for Second Quarter and Half-Year Ended 31 July 2015
Accessibility: Skip TopNav Summit Therapeutics Reports Financial Results for Second Quarter and Half-Year Ended 31 July 2015 August 27, 2015 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit' or the 'Company') SUMMIT THERAPEUTICS REP
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS TO REPORT SECOND QUARTER 2015 FINANCIAL RESULTS ON 27 AUGUST 2015 Oxford, UK, 24 August 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the dr
Summit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS TO REPORT SECOND QUARTER 2015 FINANCIAL RESULTS ON 27 AUGUST 2015 Oxford, UK, 24 August 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies
Read more →SMMTSummit Therapeutics to Report Second Quarter 2015 Financial Results on 27 August 2015
OXFORD, United Kingdom, Aug. 24, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its second quarter financial re
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS ANNOUNCES PHASE 1B MODIFIED DIET CLINICAL TRIAL ACHIEVES PRIMARY OBJECTIVE IN DUCHENNE MUSCULAR DYSTROPHY Primary Objective Met; Plasma Absorption of
Summit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS ANNOUNCES PHASE 1B MODIFIED DIET CLINICAL TRIAL ACHIEVES PRIMARY OBJECTIVE IN DUCHENNE MUSCULAR DYSTROPHY Oxford, UK, 17 August 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and
Read more →SMMTSummit Therapeutics Announces Phase 1b Modified Diet Clinical Trial Achieves Primary Objective in DMD
Accessibility: Skip TopNav Summit Therapeutics Announces Phase 1b Modified Diet Clinical Trial Achieves Primary Objective in DMD August 17, 2015 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) RESULT OF ANNUAL GENERAL MEETING Oxford, UK, 29 July 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapie
Summit Therapeutics plc ( Summit or the Company ) RESULT OF ANNUAL GENERAL MEETING 29 July 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announc
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) ANNUAL GENERAL MEETING STATEMENT Oxford, UK, 14 July 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapie
Summit Therapeutics plc ( Summit or the Company ) ANNUAL GENERAL MEETING STATEMENT 14 July 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ( DMD ) and C. difficile infection
Read more →SMMTSummit Therapeutics plc Annual General Meeting Statement
OXFORD, United Kingdom, July 14, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and C. difficile infection ('CDI'), is today holding its Annual Gener
Read more →SMMTSummit Therapeutics plc : AGM Statement
Accessibility: Skip TopNav Summit Therapeutics plc : AGM Statement July 14, 2015 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") ANNUAL GENERAL MEETING STATEMENT Oxford, UK, 14 July 2015 - Summit Therapeutics pl
Read more →SMMTSummit Therapeutics Publishes Preclinical Data on Disease Modifying Potential of Utrophin Modulation in DMD
Accessibility: Skip TopNav Summit Therapeutics Publishes Preclinical Data on Disease Modifying Potential of Utrophin Modulation in DMD July 13, 2015 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEU
Read more →SMMTSummit Therapeutics Receives Fast Track Designation for Novel Antibiotic SMT19969 for CDI
Accessibility: Skip TopNav Summit Therapeutics Receives Fast Track Designation for Novel Antibiotic SMT19969 for CDI July 08, 2015 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS RECEIVES FDA
Read more →SMMTSummit Therapeutics Receives FDA Fast Track Designation for Novel Antibiotic SMT19969 in the Treatment of C. difficile Infection
OXFORD, United Kingdom, July 8, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection ('CDI'), announces that the US Food and Drug Admini
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS GRANTED KEY PATENT BY EUROPEAN PATENT OFFICE FOR UTROPHIN MODULATOR SMT C1100 IN THE TREATMENT OF DMD Patent emerges from opposition period with no op
Summit Therapeutics plc ( Summit or the Company ) THERAPEUTICS GRANTED KEY PATENT BY EUROPEAN PATENT OFFICE FOR UTROPHIN MODULATOR SMT C1100 IN THE TREATMENT OF DMD 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing the
Read more →SMMTSummit Therapeutics Granted Key Patent by European Patent Office for Utrophin Modulator SMT C1100 in the Treatment of DMD
Accessibility: Skip TopNav Summit Therapeutics Granted Key Patent by European Patent Office for Utrophin Modulator SMT C1100 in the Treatment of DMD July 07, 2015 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit' or the 'Company') S
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) DIRECTOR SHARE DEALING Oxford, UK, 22 June 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duch
Summit Therapeutics plc ( Summit or the Company ) DIRECTOR SHARE DEALING 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces that Company ha
Read more →SMMTSummit Therapeutics to Present New Preclinical Data on Utrophin Modulator Programme at PPMD Connect
Accessibility: Skip TopNav Summit Therapeutics to Present New Preclinical Data on Utrophin Modulator Programme at PPMD Connect June 19, 2015 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) AWARD OF SHARE OPTIONS Oxford, UK, 17 June 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duch
Summit Therapeutics plc ( Summit or the Company ) Oxford, UK, 17 June 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces that on 16 June 20
Read more →SMMTSummit to Present at JMP Securities Life Sciences Conference
OXFORD, United Kingdom, June 15, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces that Mr Erik Ostrowski, Summit's Chief
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS REPORTS FIRST QUARTER RESULTS FOR THE THREE MONTHS ENDED 30 APRIL 2015 Oxford, UK, 11 June 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the
Summit Therapeutics plc ( Summit or the Company ) THERAPEUTICS REPORTS FIRST QUARTER RESULTS FOR THE THREE MONTHS ENDED 30 APRIL 2015 Oxford, UK, 11 June 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for
Read more →SMMTSummit Therapeutics Reports First Quarter Results for the Three Months Ended 30 April 2015
OXFORD, United Kingdom, June 11, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and C. difficile infection ('CDI'), today reports its financial resul
Read more →SMMTSummit Therapeutics to Report First Quarter 2015 Financial Results on 11 June 2015
OXFORD, United Kingdom, June 5, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its first quarter financial resu
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS TO REPORT FIRST QUARTER 2015 FINANCIAL RESULTS ON 11 JUNE 2015 Oxford, UK, 5 June 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug dis
Summit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS TO REPORT FIRST QUARTER 2015 FINANCIAL RESULTS ON 11 JUNE 2015 Oxford, UK, 5 June 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) PUBLICATION OF UK ANNUAL REPORT AND NOTICE OF ANNUAL GENERAL MEETING Oxford, UK, 1 June 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and dev
Summit Therapeutics plc ( Summit or the Company ) PUBLICATION OF UK ANNUAL REPORT AND NOTICE OF ANNUAL GENERAL MEETING Oxford, UK, 1 June 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscul
Read more →SMMTSummit Therapeutics plc Files US Annual Report Form 20F
Accessibility: Skip TopNav Summit Therapeutics plc Files US Annual Report Form 20F May 08, 2015 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS FILES US ANNUAL REPORT FORM 20-F Oxford, UK, 8
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE FISCAL YEAR ENDED 31 JANUARY 2015 Oxford, UK, 6 May 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug
Summit Therapeutics plc ( Summit or the Company ) THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE FISCAL YEAR ENDED 31 JANUARY 2015 Oxford, UK, 6 May 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duch
Read more →SMMTSummit Therapeutics Reports Financial Results for the Fiscal Year Ended 31 January 2015
Accessibility: Skip TopNav Summit Therapeutics Reports Financial Results for the Fiscal Year Ended 31 January 2015 May 06, 2015 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS REPORTS FINANCIA
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS GRANTED KEY PATENT FOR NOVEL ANTIBIOTIC SMT19969 FOR THE TREATMENT OF C. DIFFICILE INFECTION Oxford, UK, 30 April 2015 Summit Therapeutics plc (AIM: S
Summit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS GRANTED KEY PATENT FOR NOVEL ANTIBIOTIC SMT19969 FOR THE TREATMENT OF C. DIFFICILE INFECTION Oxford, UK, 30 April 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development co
Read more →SMMTSummit Therapeutics Provides Notice of Full Year Financial Results
OXFORD, United Kingdom, May 1, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be announcing its full year financial results
Read more →SMMTSummit Therapeutics Granted Key Patent for Novel Antibiotic SMT19969 for the Treatment of C. Difficile Infection
OXFORD, United Kingdom, April 30, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (Nasdaq:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ("CDI") announces that the United States
Read more →SMMTSummit Therapeutics Granted Key Patent for Novel C. difficile Antibiotic SMT19969
Accessibility: Skip TopNav Summit Therapeutics Granted Key Patent for Novel C. difficile Antibiotic SMT19969 April 30, 2015 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS GRANTED KEY PATENT F
Read more →SMMTSummit to Present at Needham & Company's Annual Healthcare Conference
Accessibility: Skip TopNav Summit to Present at Needham & Company's Annual Healthcare Conference April 07, 2015 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT TO PRESENT AT NEEDHAM AND COMPANY'S ANNUAL HE
Read more →SMMTSummit to Present at Needham and Company's Annual Healthcare Conference
OXFORD, United Kingdom, April 7, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (Nasdaq:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces that Mr. Glyn Edwards, Summit's Chief E
Read more →SMMTSummit Therapeutics plc ( Summit or the Company ) SUMMIT THERAPEUTICS ANNOUNCES EXERCISE OF OVER-ALLOTMENT OPTION Oxford, UK
Summit Therapeutics plc SUMMIT THERAPEUTICS ANNOUNCES EXERCISE OF OVER-ALLOTMENT OPTION Oxford, UK, March 18, 2015 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile
Read more →SMMTSummit Therapeutics Announces Exercise of Over-Allotment Option
Accessibility: Skip TopNav Summit Therapeutics Announces Exercise of Over-Allotment Option March 18, 2015 14:15 ET Summit Therapeutics plc Summit Therapeutics plc NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO
Read more →SMMTSummit Therapeutics Announces the Closing of its US Initial Public Offering
Accessibility: Skip TopNav Summit Therapeutics Announces the Closing of its US Initial Public Offering March 10, 2015 12:45 ET Summit Therapeutics plc Summit Therapeutics plc NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTI
Read more →SMMTSummit Therapeutics Announces Pricing of US Initial Public Offering and NASDAQ Listing
Accessibility: Skip TopNav Summit Therapeutics Announces Pricing of US Initial Public Offering and NASDAQ Listing March 05, 2015 02:00 ET Summit Therapeutics plc Summit Therapeutics plc NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY
Read more →SMMTSummit Therapeutics PLC (Nasdaq: SMMT) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, March 5, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics PLC (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection, will visit the Nasdaq MarketSite in Times Square in celebration of its tr
Read more →SMMTSummit Therapeutics Files Amended Registration Statement for NASDAQ Listing and US Offering
Accessibility: Skip TopNav Summit Therapeutics Files Amended Registration Statement for NASDAQ Listing and US Offering February 23, 2015 02:02 ET Summit Therapeutics plc Summit Therapeutics plc NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR
Read more →SMMTSummit Therapeutics Appoints Mr David Wurzer as a Non-Executive Director
Accessibility: Skip TopNav Summit Therapeutics Appoints Mr David Wurzer as a Non-Executive Director February 23, 2015 02:01 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit' or the 'Company') SUMMIT APPOINTS MR DAVID WURZER AS NON-EXECUTI
Read more →SMMTSummit Announces First Patients Dosed in Phase 1b Modified Diet Clinical Trial of SMT C1100 for DMD
Accessibility: Skip TopNav Summit Announces First Patients Dosed in Phase 1b Modified Diet Clinical Trial of SMT C1100 for DMD February 20, 2015 02:01 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ('Summit' or the 'Company') SUMMIT ANNOUNCES TH
Read more →SMMTSummit Corporation PLC : Result of General Meeting
Accessibility: Skip TopNav Summit Corporation PLC : Result of General Meeting February 19, 2015 09:30 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or the 'Company') RESULT OF GENERAL MEETING Oxford, UK, 19 February 2015 - Summit (AIM
Read more →SMMTSummit Corporation PLC : Notice of General Meeting
Accessibility: Skip TopNav Summit Corporation PLC : Notice of General Meeting February 03, 2015 09:30 ET Summit Therapeutics plc Summit Therapeutics plc NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOUL
Read more →SMMTSummit Files Registration Statement for NASDAQ Listing and US Offering of ADSs
Accessibility: Skip TopNav Summit Files Registration Statement for NASDAQ Listing and US Offering of ADSs February 02, 2015 02:01 ET Summit Therapeutics plc Summit Therapeutics plc NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURI
Read more →SMMTSummit Corporation PLC : Third Quarter Results for Nine Months Ended 31 October 2014
Accessibility: Skip TopNav Summit Corporation PLC : Third Quarter Results for Nine Months Ended 31 October 2014 February 02, 2015 02:00 ET Summit Therapeutics plc Summit Therapeutics plc NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM AN
Read more →SMMTSummit Corporation PLC : Award of Options
Accessibility: Skip TopNav Summit Corporation PLC : Award of Options January 23, 2015 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or the 'Company') Oxford, UK, 23 January 2015 - Summit (AIM: SUMM), the drug discovery and develo
Read more →SMMTSummit Corporation PLC : Share Option Award
Accessibility: Skip TopNav Summit Corporation PLC : Share Option Award December 24, 2014 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or the 'Company') Oxford, UK, 24 December 2014 - Summit (AIM: SUMM), the drug discovery and de
Read more →SMMTSummit Considering Potential US Registered Public Offering and Stock Exchange Listing
Accessibility: Skip TopNav Summit Considering Potential US Registered Public Offering and Stock Exchange Listing December 19, 2014 06:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT CONSIDERING POTENTIAL U.S.
Read more →SMMTSummit Receives Regulatory Approval to Initiate a Modified Diet Clinical Trial of SMT C1100 in DMD Patients
Accessibility: Skip TopNav Summit Receives Regulatory Approval to Initiate a Modified Diet Clinical Trial of SMT C1100 in DMD Patients December 11, 2014 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT RECEI
Read more →SMMTSummit to Present Company Overview at the Oppenheimer Annual Healthcare Conference
Accessibility: Skip TopNav Summit to Present Company Overview at the Oppenheimer Annual Healthcare Conference December 05, 2014 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or the 'Company') SUMMIT TO PRESENT COMPANY OVERVIEW AT
Read more →SMMTSummit Corporation PLC : Directorate change
Accessibility: Skip TopNav Summit Corporation PLC : Directorate change December 03, 2014 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') Oxford, UK, 3 December 2014 - Summit (AIM: SUMM), the drug discovery and dev
Read more →SMMTSummit Corporation PLC : Exercise of Options
Accessibility: Skip TopNav Summit Corporation PLC : Exercise of Options October 29, 2014 03:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') Oxford, UK, 29 October 2014 - Summit (AIM: SUMM) announces that on 28 Octobe
Read more →SMMTSummit Reports Positive Data on it Utrophin Modulation Programme for the Treatment of DMD at 2014 WMS Congress
Accessibility: Skip TopNav Summit Reports Positive Data on it Utrophin Modulation Programme for the Treatment of DMD at 2014 WMS Congress October 08, 2014 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT REP
Read more →SMMTSummit Appoints Valerie Andrews as a Non-Executive Director
Accessibility: Skip TopNav Summit Appoints Valerie Andrews as a Non-Executive Director September 19, 2014 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT APPOINTS VALERIE ANDREWS AS A NON-EXECUTIVE DIRECTOR
Read more →SMMTSummit Presents New Positive Preclinical Data on SMT19969 for C. difficile at ICAAC 2014
Accessibility: Skip TopNav Summit Presents New Positive Preclinical Data on SMT19969 for C. difficile at ICAAC 2014 September 08, 2014 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT PRESENTS NEW POSITIVE P
Read more →SMMTSummit Corporation PLC : Half-yearly report
Accessibility: Skip TopNav Summit Corporation PLC : Half-yearly report September 04, 2014 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 JULY 2014 Oxford, UK, 4 Septem
Read more →SMMTSummit Corporation PLC : Holding(s) in Company
Accessibility: Skip TopNav Summit Corporation PLC : Holding(s) in Company September 02, 2014 05:02 ET Summit Therapeutics plc Summit Therapeutics plc TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to whi
Read more →SMMTSummit Corporation PLC : Notice of Results
Accessibility: Skip TopNav Summit Corporation PLC : Notice of Results September 01, 2014 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or the 'Company') NOTICE OF INTERIM RESULTS Oxford, UK, 1 September 2014 - Summit (AIM: SUMM)
Read more →SMMTSummit to Present at the Canaccord Genuity 34th Annual Growth Conference
Accessibility: Skip TopNav Summit to Present at the Canaccord Genuity 34th Annual Growth Conference August 07, 2014 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or the 'Company') SUMMIT TO PRESENT COMPANY OVERVIEW AT THE CANACCO
Read more →SMMTSummit Corporation PLC : Update on Capital Reorganisation Timetable
Accessibility: Skip TopNav Summit Corporation PLC : Update on Capital Reorganisation Timetable July 18, 2014 10:10 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or the 'Company') UPDATE ON CAPITAL REORGANISATION Oxford, UK, 18 July 20
Read more →SMMTSummit Corporation PLC : Award of Share Options
Accessibility: Skip TopNav Summit Corporation PLC : Award of Share Options July 16, 2014 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or the 'Company') AWARD OF SHARE OPTIONS Oxford, UK, 16 July 2014 - Summit (AIM: SUMM), the d
Read more →SMMTSummit Presents New Data from Phase 1b Clinical Trial of SMT C1100 for Treatment of DMD
Accessibility: Skip TopNav Summit Presents New Data from Phase 1b Clinical Trial of SMT C1100 for Treatment of DMD July 07, 2014 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or the 'Company') SUMMIT PRESENTS NEW DATA FROM PHASE
Read more →SMMTSummit Corporation PLC : Total voting rights
Accessibility: Skip TopNav Summit Corporation PLC : Total voting rights July 04, 2014 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or the 'Company') Oxford, UK, 4 July 2014 - Summit (AIM: SUMM), a drug discovery and development
Read more →SMMTSummit Release AGM Statement
Accessibility: Skip TopNav Summit Release AGM Statement July 03, 2014 04:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or the 'Company') ANNUAL GENERAL MEETING STATEMENT Oxford, UK, 3 July 2014 - Summit (AIM: SUMM), a drug discover
Read more →SMMTSummit Corporation PLC : Result of AGM
Accessibility: Skip TopNav Summit Corporation PLC : Result of AGM July 03, 2014 09:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or the 'Company') ANNUAL GENERAL MEETING RESULTS Oxford, UK, 3 July 2014 - Summit (AIM: SUMM), a drug
Read more →SMMTSummit Announces First Patients Dosed in a Phase 2 Clinical Trial of Novel C. difficile Antibiotic
Accessibility: Skip TopNav Summit Announces First Patients Dosed in a Phase 2 Clinical Trial of Novel C. difficile Antibiotic July 03, 2014 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or the 'Company') SUMMIT ANNOUNCES FIRST PA
Read more →SMMTSummit Corporation PLC : Share Option Awards
Accessibility: Skip TopNav Summit Corporation PLC : Share Option Awards June 24, 2014 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or the 'Company') Oxford, UK, 24 June 2014 - Summit (AIM: SUMM), a drug discovery and development
Read more →SMMTSummit Appoints Erik Ostrowski as Chief Financial Officer
Accessibility: Skip TopNav Summit Appoints Erik Ostrowski as Chief Financial Officer June 23, 2014 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or the 'Company') SUMMIT APPOINTS ERIK OSTROWSKI AS CHIEF FINANCIAL OFFICER Oxford,
Read more →SMMTSummit to Present Company Overview at JMP Securities Healthcare Conference
Accessibility: Skip TopNav Summit to Present Company Overview at JMP Securities Healthcare Conference June 19, 2014 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or the 'Company') SUMMIT TO PRESENT COMPANY OVERVIEW AT JMP SECURIT
Read more →SMMTSummit Establishes US Office and Strengthens its Drug Development Team
Accessibility: Skip TopNav Summit Establishes US Office and Strengthens its Drug Development Team June 17, 2014 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or the 'Company') SUMMIT ESTABLISHES US OFFICE IN CAMBRIDGE, MASSACHUSE
Read more →SMMTSummit Corporation PLC : Notice of AGM and Proposed Capital Reorganisation
Accessibility: Skip TopNav Summit Corporation PLC : Notice of AGM and Proposed Capital Reorganisation June 03, 2014 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or the 'Company') NOTICE OF ANNUAL GENERAL MEETING AND PROPOSED CA
Read more →SMMTSummit Appoints Leopoldo Zambeletti as a Non-Executive Director
Accessibility: Skip TopNav Summit Appoints Leopoldo Zambeletti as a Non-Executive Director May 30, 2014 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT APPOINTS MR LEOPOLDO ZAMBELETTI AS A NON-EXECUTIVE DIR
Read more →SMMTSummit Report Preliminary Results from Phase 1b Clinical Trial of SMT C1100 for DMD
Accessibility: Skip TopNav Summit Report Preliminary Results from Phase 1b Clinical Trial of SMT C1100 for DMD May 21, 2014 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT REPORTS PRELIMINARY RESULTS FROM P
Read more →SMMTSummit Presents New Positive Non-Clinical Efficacy Data at ECCMID
Accessibility: Skip TopNav Summit Presents New Positive Non-Clinical Efficacy Data at ECCMID May 12, 2014 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT PRESENTS NEW POSITIVE NON-CLINICAL EFFICACY DATA AT
Read more →SMMTSummit Corporation PLC : Preliminary Results
Accessibility: Skip TopNav Summit Corporation PLC : Preliminary Results April 30, 2014 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') PRELIMINARY RESULTS FOR THE YEAR ENDED 31 JANUARY 2014 Oxford, UK, 30 April 2
Read more →SMMTSummit Corporation PLC : Notice of Preliminary Results
Accessibility: Skip TopNav Summit Corporation PLC : Notice of Preliminary Results April 28, 2014 09:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') NOTICE OF PRELIMINARY RESULTS Oxford, UK, 28 April 2014 - Summit (A
Read more →SMMTSummit Receive FDA Clearance of IND Application for Phase 2 Study of SMT19969 to Treat CDI
Accessibility: Skip TopNav Summit Receive FDA Clearance of IND Application for Phase 2 Study of SMT19969 to Treat CDI March 18, 2014 03:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT ANNOUNCES FDA CLEARANCE O
Read more →SMMTSummit Corporation PLC : Completion of the Second Placing
Accessibility: Skip TopNav Summit Corporation PLC : Completion of the Second Placing March 04, 2014 11:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') COMPLETION OF THE SECOND PLACING Oxford, UK, 4 March 2014 - Summ
Read more →SMMTSummit Corporation PLC : Change of Adviser
Accessibility: Skip TopNav Summit Corporation PLC : Change of Adviser March 04, 2014 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') Oxford, UK, 4 March 2014 - Summit (AIM: SUMM), a drug discovery and development
Read more →SMMTSummit Corporation PLC : Completion of First Placing
Accessibility: Skip TopNav Summit Corporation PLC : Completion of First Placing March 03, 2014 09:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or the 'Company') COMPLETION OF FIRST PLACING Oxford, UK, 3 March 2014 - Summit (AIM: S
Read more →SMMTSummit Corporation PLC : Result of Offer for Subscription to Qualifying Shareholders
Accessibility: Skip TopNav Summit Corporation PLC : Result of Offer for Subscription to Qualifying Shareholders February 26, 2014 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') RESULT OF OFFER FOR SUBSCRIPTION TO
Read more →SMMTSummit Corporation PLC : Presentation at Cowen & Co 34th Annual Healthcare Conference
Accessibility: Skip TopNav Summit Corporation PLC : Presentation at Cowen & Co 34th Annual Healthcare Conference February 26, 2014 09:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT TO PRESENT AT THE COWEN AND
Read more →SMMTSummit Corporation PLC : Circular and Notice of General Meeting
Accessibility: Skip TopNav Summit Corporation PLC : Circular and Notice of General Meeting February 13, 2014 09:00 ET Summit Therapeutics plc Summit Therapeutics plc NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE
Read more →SMMTSummit Corporation PLC : Issue of Equity
Accessibility: Skip TopNav Summit Corporation PLC : Issue of Equity February 11, 2014 13:29 ET Summit Therapeutics plc Summit Therapeutics plc NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITU
Read more →SMMTSummit Corporation PLC : Director Disclosure Update
Summit Corporation plc ('Summit' or 'the Company') DIRECTOR UPDATE: NOTIFICATION UNDER AIM RULE 17 AND SCHEDULE 2(g) Oxford, UK, 27 January 2014 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile
Read more →SMMTSummit Announces First Patient Dosed in a Phase 1b Clinical Trial of SMT C1100 for Treatment of DMD
Accessibility: Skip TopNav Summit Announces First Patient Dosed in a Phase 1b Clinical Trial of SMT C1100 for Treatment of DMD December 09, 2013 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT ANNOUNCES FIR
Read more →SMMTSummit and the University of Oxford Enter Strategic Alliance to Develop Treatments for DMD
Accessibility: Skip TopNav Summit and the University of Oxford Enter Strategic Alliance to Develop Treatments for DMD November 25, 2013 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT AND THE UNIVERSITY OF
Read more →SMMTSummit and Joining Jack Enter Funding Agreement to Develop Novel Biomarkers for DMD
Accessibility: Skip TopNav Summit and Joining Jack Enter Funding Agreement to Develop Novel Biomarkers for DMD November 05, 2013 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT AND JOINING JACK ENTER FUNDIN
Read more →SMMTSummit Receives Regulatory Approval to Start Phase 1b of SMT C1100 in DMD Patients
Accessibility: Skip TopNav Summit Receives Regulatory Approval to Start Phase 1b of SMT C1100 in DMD Patients November 01, 2013 03:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT RECEIVES REGULATORY APPROVAL T
Read more →SMMTSummit to Present Clinical and Biomarker Programmes for DMD at WMS Congress
Accessibility: Skip TopNav Summit to Present Clinical and Biomarker Programmes for DMD at WMS Congress September 30, 2013 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT TO PRESENT CLINICAL AND BIOMARKER DE
Read more →SMMTSummit Corporation PLC : Change of Nomad
Accessibility: Skip TopNav Summit Corporation PLC : Change of Nomad September 26, 2013 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') APPOINTMENT OF NOMINATED ADVISER Oxford, UK, 26 September 2013 - Summit (AIM:
Read more →SMMTSummit Present New Data on C. difficile Antibiotic SMT19969 at ICAAC 2013
Accessibility: Skip TopNav Summit Present New Data on C. difficile Antibiotic SMT19969 at ICAAC 2013 September 11, 2013 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT PRESENTS NEW PRECLINICAL AND CLINICAL
Read more →SMMTSummit to Present New Data on C difficile Antibiotic at ICAAC 2013
Accessibility: Skip TopNav Summit to Present New Data on C difficile Antibiotic at ICAAC 2013 September 04, 2013 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT TO PRESENT NEW DATA ON C. DIFFICILE ANTIBIOTI
Read more →SMMTSummit Granted Key Composition of Matter Patent for SMT C1100 in the Treatment of DMD
Accessibility: Skip TopNav Summit Granted Key Composition of Matter Patent for SMT C1100 in the Treatment of DMD August 28, 2013 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT GRANTED KEY COMPOSITION OF MA
Read more →SMMTSummit Corporation PLC : Exercise of Warrants
Accessibility: Skip TopNav Summit Corporation PLC : Exercise of Warrants August 23, 2013 09:30 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ("Summit" or "the Company") EXERCISE OF WARRANTS Oxford, UK, 23 August 2013, Summit (AIM: SUMM), a drug
Read more →SMMTSummit Corporation PLC : Interim Financial Results
Accessibility: Skip TopNav Summit Corporation PLC : Interim Financial Results August 22, 2013 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ("Summit" or "the Company") INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 JULY 2013 Oxford, UK, 22 A
Read more →SMMTSummit Corporation PLC : Notice of Interim Results
Accessibility: Skip TopNav Summit Corporation PLC : Notice of Interim Results August 21, 2013 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') NOTICE OF INTERIM RESULTS Oxford, UK, 21 August 2013 - Summit (AIM: SU
Read more →SMMTSummit Granted US Patent for Utrophin Modulator SMT C1100 in Treatment of DMD
Accessibility: Skip TopNav Summit Granted US Patent for Utrophin Modulator SMT C1100 in Treatment of DMD August 07, 2013 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') US PATENT GRANTED FOR UTROPHIN MODULATOR SMT
Read more →SMMTSummit to Present at Wedbush Securities Life Science Conference
Accessibility: Skip TopNav Summit to Present at Wedbush Securities Life Science Conference August 06, 2013 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT TO PRESENT AT WEDBUSH SECURITIES LIFE SCIENCES CONF
Read more →SMMTSummit Awarded 2.4m from the UK Biomedical Catalyst Fund
Accessibility: Skip TopNav Summit Awarded £2.4m from the UK Biomedical Catalyst Fund July 31, 2013 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT AWARDED £2.4 MILLION FROM THE UK BIOMEDICAL CATALYST FUND T
Read more →SMMTSummit Corporation PLC : Director Shareholding
Accessibility: Skip TopNav Summit Corporation PLC : Director Shareholding July 26, 2013 09:15 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') DIRECTOR SHAREHOLDINGS Oxford, UK, 26 July 2013 - Summit (AIM: SUMM), a drug
Read more →SMMTSummit Enter AUD 1.25m Funding Agreement with Save Our Sons to Support DMD Programme
Accessibility: Skip TopNav Summit Enter AUD 1.25m Funding Agreement with Save Our Sons to Support DMD Programme July 18, 2013 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT ENTER AUD 1.25M FUNDING AGREEMEN
Read more →SMMTSummit to Present at JMP Securities Healthcare Conference
Accessibility: Skip TopNav Summit to Present at JMP Securities Healthcare Conference July 01, 2013 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT TO PRESENT COMPANY OVERVIEW AT INTERNATIONAL HEALTHCARE CON
Read more →SMMTSummit Achieves Clinical Milestone Triggering 740,000 Payment from Wellcome Trust
Accessibility: Skip TopNav Summit Achieves Clinical Milestone Triggering £740,000 Payment from Wellcome Trust June 17, 2013 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT ACHIEVES CLINICAL MILESTONE TRIGGE
Read more →SMMTSummit Appoints Dr David Roblin as Chief Medical Officer
Accessibility: Skip TopNav Summit Appoints Dr David Roblin as Chief Medical Officer June 12, 2013 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT APPOINTS DR DAVID ROBLIN AS CHIEF MEDICAL OFFICER Oxford, U
Read more →SMMTSummit Corporation PLC : Notice of AGM
Accessibility: Skip TopNav Summit Corporation PLC : Notice of AGM May 07, 2013 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') NOTICE OF ANNUAL GENERAL MEETING Oxford, UK, 7 May 2013 - Summit (AIM: SUMM), a drug
Read more →SMMTSummit Corporation PLC : Research Update
Accessibility: Skip TopNav Summit Corporation PLC : Research Update April 17, 2013 05:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') NEW POSITIVE DATA ON C. DIFFICILE ANTIBIOTIC PROGRAMME TO BE PRESENTED AT INTERNAT
Read more →SMMTSummit Corporation PLC : New Data Reported from OGA Inhibitor Programme
Accessibility: Skip TopNav Summit Corporation PLC : New Data Reported from OGA Inhibitor Programme March 11, 2013 03:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') NEW DATA REPORTED FROM PRECLINICAL EFFICACY STUDY O
Read more →SMMTSummit Corporation PLC : Utrophin Biomarker Collaboration for DMD Programme Entered
Accessibility: Skip TopNav Summit Corporation PLC : Utrophin Biomarker Collaboration for DMD Programme Entered February 06, 2013 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT AND CHILDREN'S NATIONAL MEDIC
Read more →SMMTSummit Corporation PLC : Nomura Code Appointed Nomad and Joint Broker
Accessibility: Skip TopNav Summit Corporation PLC : Nomura Code Appointed Nomad and Joint Broker January 25, 2013 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') NOMURA CODE APPOINTED AS NOMAD AND JOINT BROKER Ox
Read more →SMMTSummit Corporation PLC : Summit Appoints Mr Jim Mellon and Dr Frank Armstrong as Non-Executive Directors
Accessibility: Skip TopNav Summit Corporation PLC : Summit Appoints Mr Jim Mellon and Dr Frank Armstrong as Non-Executive Directors November 22, 2012 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT APPOINTS
Read more →SMMTSummit Corporation PLC : Adviser Change of Name
Accessibility: Skip TopNav Summit Corporation PLC : Adviser Change of Name November 20, 2012 05:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') ADVISER CHANGE OF NAME Oxford, UK, 20 November 2012 - Summit (AIM: SUMM
Read more →SMMTSummit Corporation PLC : Summit to Present at Proactive Investors One2One Investor Forum
Accessibility: Skip TopNav Summit Corporation PLC : Summit to Present at Proactive Investors One2One Investor Forum November 14, 2012 09:30 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') INVESTOR PRESENTATION Oxford,
Read more →SMMTSummit Corporation PLC : Repeat Dosing of SMT C1100 for Treatment of DMD Meets Endpoints in Phase 1 Trial
Accessibility: Skip TopNav Summit Corporation PLC : Repeat Dosing of SMT C1100 for Treatment of DMD Meets Endpoints in Phase 1 Trial November 07, 2012 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') REPEAT DOSING
Read more →SMMTSummit Corporation PLC : Initiation of Phase 1 Clinical Trial of Antibiotic to Treat C. difficile Infection
Accessibility: Skip TopNav Summit Corporation PLC : Initiation of Phase 1 Clinical Trial of Antibiotic to Treat C. difficile Infection October 31, 2012 03:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT ANNOUN
Read more →SMMTSummit Corporation PLC : 4.0 million Award from Wellcome Trust to Support C. difficile Antibiotic
Accessibility: Skip TopNav Summit Corporation PLC : £4.0 million Award from Wellcome Trust to Support C. difficile Antibiotic October 22, 2012 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT AWARDED UP TO £
Read more →SMMTSummit Corporation PLC : Launch of New Corporate Website
Accessibility: Skip TopNav Summit Corporation PLC : Launch of New Corporate Website October 15, 2012 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT LAUNCHES NEW CORPORATE WEBSITE Oxford, UK, 15 October 20
Read more →SMMTSummit Corporation PLC : Technology License Agreement Signed wth Bristol-Myers Squibb
Accessibility: Skip TopNav Summit Corporation PLC : Technology License Agreement Signed wth Bristol-Myers Squibb September 11, 2012 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT ENTERS TECHNOLOGY LICENSE
Read more →SMMTSummit Corporation PLC : Interim Results
Accessibility: Skip TopNav Summit Corporation PLC : Interim Results September 06, 2012 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ("Summit" or "the Company") INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 JULY 2012 Oxford, UK, 6 September
Read more →SMMTSummit Corporation PLC : Corporate Strategy Update
Accessibility: Skip TopNav Summit Corporation PLC : Corporate Strategy Update September 06, 2012 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT UPDATES CORPORATE STRATEGY TO FOCUS ON DEVELOPMENT OF CLINICA
Read more →SMMTSummit Corporation PLC : Notification of Grant Award from UK Technology Strategy Board
Accessibility: Skip TopNav Summit Corporation PLC : Notification of Grant Award from UK Technology Strategy Board August 02, 2012 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT NOTIFIED OF GRANT AWARD FROM
Read more →SMMTSummit Corporation PLC : AGM Statement
Accessibility: Skip TopNav Summit Corporation PLC : AGM Statement July 18, 2012 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') ANNUAL GENERAL MEETING STATEMENT Oxford, UK, 18 July 2012 - Summit (AIM: SUMM), a UK
Read more →SMMTSummit Corporation PLC : New data presented on OGA inhibition at Alzheimer's Association International Conference
Accessibility: Skip TopNav Summit Corporation PLC : New data presented on OGA inhibition at Alzheimer's Association International Conference July 17, 2012 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT PRE
Read more →SMMTSummit Corporation PLC : Presentation at International Muscular Dystrophy Conference
Accessibility: Skip TopNav Summit Corporation PLC : Presentation at International Muscular Dystrophy Conference June 29, 2012 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT TO PRESENT AT INTERNATIONAL MUSC
Read more →SMMTSummit Corporation PLC : Director/PDMR Shareholding
Accessibility: Skip TopNav Summit Corporation PLC : Director/PDMR Shareholding June 14, 2012 09:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') DIRECTOR/PDMR SHAREHOLDING: PURCHASE OF SHARES Oxford, UK, 14 June 2012
Read more →SMMTSummit Corporation PLC : Summit achieves SMT C1100 Phase 1 dosing milestone that triggers milestone payment
Accessibility: Skip TopNav Summit Corporation PLC : Summit achieves SMT C1100 Phase 1 dosing milestone that triggers milestone payment June 12, 2012 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT ACHIEVES
Read more →SMMTSummit Corporation PLC : Summit Announces Initiation of Phase 1 Trial for the Treatment of Duchenne Muscular Dystrophy
Accessibility: Skip TopNav Summit Corporation PLC : Summit Announces Initiation of Phase 1 Trial for the Treatment of Duchenne Muscular Dystrophy May 25, 2012 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') Summit
Read more →SMMTSummit Corporation PLC : Holding(s) in Company (amendment)
Accessibility: Skip TopNav Summit Corporation PLC : Holding(s) in Company (amendment) April 27, 2012 11:07 ET Summit Therapeutics plc Summit Therapeutics plc This announcement replaces RNS Number HUG1606130, which was released at 7.01 a.m. on 26 April 2012. There is no chang
Read more →SMMTSummit Corporation PLC: Holding(s) in Company
Accessibility: Skip TopNav Summit Corporation PLC: Holding(s) in Company April 26, 2012 02:00 ET Summit Therapeutics plc Summit Therapeutics plc TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which vo
Read more →SMMTSummit Corporation PLC : SMT C1100 Receives Regulatory Approval to Enter Phase I Clinical Trial
Accessibility: Skip TopNav Summit Corporation PLC : SMT C1100 Receives Regulatory Approval to Enter Phase I Clinical Trial April 24, 2012 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') SUMMIT RECEIVES REGULATORY
Read more →SMMTSummit Corporation PLC : Application to Trading
Accessibility: Skip TopNav Summit Corporation PLC : Application to Trading April 23, 2012 06:30 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') APPLICATION TO TRADING Oxford, UK, 23 April 2012, Summit (AIM: SUMM), a UK
Read more →SMMTSummit Corporation PLC : Posting to Shareholders the Circular and Notice of General Meeting
Accessibility: Skip TopNav Summit Corporation PLC : Posting to Shareholders the Circular and Notice of General Meeting April 05, 2012 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') POSTING OF SHAREHOLDER CIRCULAR
Read more →SMMTSummit Corporation PLC : Preliminary Results for the Year Ended 31 January 2012
Summit Corporation plc ("Summit" or "the Company") PRELIMINARY RESULTS FOR THE YEAR ENDED 31 JANUARY 2012 Oxford, UK, 4 April 2012, Summit (AIM: SUMM), a UK drug discovery company with a portfolio of drug programmes and an innovative Seglin(TM) technology platform for the disc
Read more →SMMTSummit Corporation PLC : Proposed Placing of New Ordinary Shares to Raise 5.0m
Accessibility: Skip TopNav Summit Corporation PLC : Proposed Placing of New Ordinary Shares to Raise £5.0m April 04, 2012 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') PROPOSED PLACING OF NEW ORDINARY SHARES TO
Read more →SMMTSummit Corporation PLC : Directorate change - Appointment of Glyn Edwards as CEO
Accessibility: Skip TopNav Summit Corporation PLC : Directorate change - Appointment of Glyn Edwards as CEO April 04, 2012 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') GLYN EDWARDS APPOINTED AS CHIEF EXECUTIVE
Read more →SMMTSummit Corporation PLC : Research Update on Alzheimer's Disease Programme
Accessibility: Skip TopNav Summit Corporation PLC : Research Update on Alzheimer's Disease Programme March 06, 2012 02:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Corporation plc ('Summit' or 'the Company') RESEARCH UPDATE ON ALZHEIMER'S DISEASE PROGRAMME
Read more →Competitive Position
How SMMT ranks across every disease it competes inCompetitive Position is a premium feature
See how SMMT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial